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with	 rheumatoid	 arthritis	 (RA)	 varies	 between	 patients.	 Incidence	 of	 sustained	




Aims.	This	 thesis	aims	to	 identify	 incidence	of	sustained	remission	and	 low	disease	





associated	 with,	 sustained	 remission	 in	 patients	 with	 RA	 taking	 anti-TNF	 therapy.	
Results	informed	a	subsequent	analysis	of	data	extracted	from	the	British	Society	for	
Rheumatology	 Biologics	 Register	 for	 Rheumatoid	 Arthritis	 (BSRBR-RA).	 I	 used	 two	
approaches	 to	 examine	 sustained	 remission	 and	 LDA.	 Firstly,	 pre-defined	 DAS28	
thresholds	were	used	to	identify	individuals	in	sustained	remission	and	LDA.	Secondly,	





and	 26.3%	 respectively),	 but	 had	 improved	 significantly	 over	 time.	 	 Significant	
associations	were	identified	between	the	candidate	variables	and	sustained	remission	






























































































































This	definition	highlights	 that	a	 successful	medical	 treatment	 is	one	 that	 cures,	 and	
restores	health,	with	no	time	specification	for	how	long	the	restoration	of	health	should	









the	 individual	 patient	 level.	 Seeking	 greater	 personalisation	 of	 treatment,	 using	
putative	 molecular	 and	 serum	 biomarkers	 to	 guide	 therapy,	 is	 an	 attractive	 and	











1.1 A brief history of RA 
	
RA	 is	 often	 thought	 of	 as	 a	 ‘young’	 disease.	 The	 first	 description	 of	 the	 disease	 in	
modern	medicine	was	in	1800	by	Augustin	Landre-Baeuvais,	working	at	Saltpêtrière	
asylum,	with	his	 thesis	on	 “Primary	Asthenic	Gout”	 (2).	Landre-Baevais	described	a	
constellation	of	symptoms	that	are	now	identified	as	RA,	although,	as	the	title	of	his	
thesis	purports,	the	condition	was,	at	that	stage,	considered	a	forme	fruste	of	gout.	His	
work	 paved	 the	 way	 for	 others	 to	 investigate	 this	 previously	 uncharacterised	
condition,	and	in	1859,	Alfred	Garrod	published	his	work	 ‘Treatise	on	the	Nature	of	
Gout	and	Rheumatic	Gout’	(3).	Garrod	had	identified	that	a	build-up	of	excess	crystals	
in	 the	blood	was	 the	primary	 cause	of	 gout.	However,	 he	 also	 identified	 a	 group	of	
patients	who	had	symptoms	similar	to	gout,	but	who	did	not	have	any	crystals	in	their	





Whether	 RA	 really	 is	 a	 ‘new’	 condition	 that	 has	 developed	 in	 the	 post-industrial	
revolution	era	remains	unclear.	One	of	the	arguments	for	RA	being	a	‘young’	condition	
is	due	to	the	relative	 lack	of	medical	records	from	historical	times	that	describe	the	
condition,	 and	 absence	 of	 paleopathlogical	 evidence	 demonstrating	 the	 classical	
erosive	 skeletal	 damage	 commonly	 associated	 with	 the	 condition	 (5).	 The	 lack	 of	
medical	record	evidence	may	have	been	due	to	the	fact	that	historically,	while	gout	was	
associated	with	wealth	and	prosperity,	RA	was	a	disease	 that,	 according	 to	Landré-
Beauvais,	 ‘resides	 in	 the	 home	 of	 the	 indigent’	 (2).	 The	 reason	 why	 RA	 was	more	




may	 have	 played	 a	 role.	 	 Financial	 barriers	 to	 accessing	 	 medical	 care	 for	 chronic	
conditions	amongst	poorer	people	might	account	for	under-documentation	of	RA	by	











disease	 (7).	 Although	 there	 have	 been	 some	 descriptions	 of	 possible	 rheumatoid	
deformities	 in	 exhumed	 skeletons	 in	 Europe	 and	 north	 Africa	 (9,10),	 ‘Old	 World’	
paleopathological	evidence	remains	sparse,	and	often	disputed.	Interestingly,	there	is	
putative	evidence	of	the	existence	of	RA	in	the	Americas	for	over	four	Millennia	with	
the	 identification	of	 likely	RA	 in	3500-year-old	skeletal	remains	 from	Alabama,	USA	
(11).			
	
Although	 RA	 was	 only	 formally	 identified	 as	 a	 distinct	 condition	 in	 the	 late	 19th	




‘In	 the	arthritis	which	generally	 shows	 itself	about	 the	age	of	 thirty-five	 there	 is	
frequently	no	great	interval	between	the	affection	of	the	hands	and	feet;	both	these	





















sixteenth	 century.	Tobacco	had	been	 smoked	by	native	Americans	 for	 thousands	of	
years	 (13),	 and	 as	 mentioned	 previously,	 there	 is	 more	 historical	 evidence	 of	 the	
condition	than	in	Europe.	Initially,	following	its	importation	to	Europe,	tobacco	use	was	
reserved	 for	 medicinal	 purposes,	 however,	 in	 the	 17th	 and	 18th	 century,	 it’s	 use	
became	more	widespread	with	smoking	for	pleasure	rather	than	for	medical	purposes	
























Following	 initial	 inflammatory	 attack	 on	 the	 synovium,	 synovial	 cells	 become	
hyperplastic	 and	 thickened,	 with	 the	 recruitment	 of	 fibroblast-like	 synoviocytes,	
neutrophils,	macrophages	and	development	of	new	blood	vessels	to	form	pannus	(20).	
Neutrophils	 and	 macrophages	 secrete	 pro-inflammatory	 cytokines	 which	 cause	
localised	 damage	 at	 the	 synovial/cartilage	 junction	 whereupon,	 the	 underlying	
cartilage	 and	bone	 can	be	 targeted	by	 the	 inflammatory	process	 (usually	by	matric	
metalloproteinases)	 which	 act	 to	 degrade	 the	 cartilage	 by	 disassembling	 type	 2	
collagen.	Chondrocyte	apoptosis	 limits	 further	the	regenerative	capacity	of	cartilage	
with	 cartilaginous	 thinning	 and	 subsequent	 joint	 space	 narrowing	 (21)	 (visible	
radiologically).	This	cartilaginous	and	bone	damage	form	the	beginnings	of	permanent	

















TNF	 is	 centrally	 involved	 in	 the	 inflammatory	cascade	and	activates	 leukocytes	and	
synovial	 fibroblasts.	 It	 activates	 endothelial	 cells	which	promotes	 the	 adhesion	 and	
entry	 of	 lymphocytes	 from	 the	 vascular	 system	 to	 the	 synovium.	 TNF	 also	 has	 a	
prominent	 role	 in	 suppressing	 regulatory	 T-cell	 function	 and	 activating	 osteoclasts	
(23).	The	primary	homeostatic	functions	of	TNF	are	in	the	defence	against	pathogens	
and	 inhibition	 of	 tumorigenesis,	 however	 it	 plays	 a	 central	 role	 in	 the	 induction	 of	
inflammatory	mediators	central	to	RA	(including	IL-6	and	NF-kB).	Activation	of	NF-kB	
promotes	 the	 transcription	of	 INF-b,	which	 in	 turn	activates	 janus	kinase	(JAK)	and	
signal	transducer	and	activator	of	transcription	(STAT)	pathways	which	promote	the	




proteins	 that	 are	 important	 in	 the	 trafficking	 if	 inflammatory	 cells.	 It	 also	 plays	 an	
important	role	in	B-cell	differentiation	that	produces	autoantibodies	in	RA	as	well	as	
promoting	and	sustaining	 the	differentiation	of	Th17	cells	 -	 important	 in	sustaining	
chronic	 immune	 responses.	One	of	 the	key	 actions	of	 IL-6	 is	 through	 the	 JAK-STAT	
pathway	 which	 can	 activate	 mitogen	 activated	 protein	 kinase	 (MAPK)	 and	
phosphatidylinositol	 3-kinase	 (PI3K)	 pathways,	 all	 of	 which	 are	 central	 to	 the	







deleterious.	 IL-1	 enhances	 the	 recruitment	 of	 inflammatory	 cells	 locally	 by	 up-
	 35	
regulating	the	expression	of	adhesion	molecules,	allowing	inflammatory	cells	to	exit	












treatment	with	one,	or	 indeed	many	disease	modifying	agents	still	 fails	 to	 ‘cure’	 the	
condition,	and	relapse	often	occurs.		
	
The	 increasing	 understanding	 of	 the	 role	 of	 cytokines,	 and	 the	 development	 of	
techniques	that	facilitated	mass-production	of	humanised	monoclonal	antibodies	that	

















The	 role	 of	 B-cells	 in	 the	 pathogenesis	 of	 RA	 remains	 elusive.	 The	 presence	 of	 B-
lymphocyte	 stimulators,	 and	 the	 B-cell	 proliferating	 ligand	 APRIL,	 all	 point	 to	 an	
important	role	of	humoral	 immunity.	The	efficacy	of	B-cell	depleting	agents	such	as	
rituximab	 in	 the	 treatment	 of	 RA	 (particularly	 ACPA	 positive	 RA)	 attest	 to	 the	

























1.3 Epidemiology of RA 
	







of	 developing	 the	 condition	 (19).	 There	 is	 strong	 epidemiological	 evidence	 of	 a	
significant	 genetic	 component	 of	 the	 disease.	 Prevalence	 in	 European	 and	 North-
American	 Caucasian	 populations	 is	 reported	 at	 0.5	 –	 1.0%	 of	 the	 population	 (34).	
However,	 by	 comparison,	 some	Native	American	 tribes	 (such	 as	 the	 Chippawa	 and	
Pima)	have	significantly	higher	prevalence	of	RA	(6.8%	and	5.3%	respectively	(35)).	
By	comparison,	the	prevalence	of	RA	in	far	eastern	countries	such	as	China	and	Japan	
are	 much	 lower	 (0.2	 -	 0.3%	 respectively)	 suggesting	 a	 genetic	 or	 environmental	
component	to	the	disease.	Prevalence	is	also	noted	to	be	very	low	across	sub-Saharan	
Africa	(35),	although	low	prevalence	in	such	countries	may	be	partially	attributable	to	
lower	 life-expectancies	 and	 limited	universal	 healthcare	 coverage	which	may	mean	
that	the	disease	is	less	likely	to	be	identified	by	research	studies.	
	
Whilst	 there	 is	a	 familial	 risk	associated	with	RA,	 it	appears	 to	be	 lower	 than	other	




Genome-wide	 studies	 have	 identified	 multiple	 associations	 between	 RA	 and	 genes	






chain	 that	 are	 located	 in	 the	 peptide-binding	 groove	 and	 	 responsible	 for	 antigen	
presentation.	 The	 reducing	 cost	 and	 increasing	 computing	 power	 have	 led	 to	 a	
dramatic	increase	in	studies	into	genetic	risk	factors	for	RA,	as	well	as	using	genetics	
platforms	 to	explore	 the	pathogenesis	of	 the	 condition.	Both	T	and	B-cell	 signalling	
pathways	 have	 been	 identified,	 and	 signalling	 pathways	 involving	 tumour	 necrosis	






acetylation	 of	 the	 genome	 acts	 to	 makes	 sections	 of	 the	 genome	 more	 or	 less	
susceptible	 to	 transcription,	 and	 environmental	 factors	 such	 as	 smoking	 have	 been	
shown	 to	 be	 potent	 inducers	 of	 acetylation	 and	 methylation,	 highlighting	 how	










Multiple	 studies	 have	 also	 suggested	 that	 exposure	 to	 the	 oral	 contraceptive	 pill	 is	







more	 severe	 disease	 (44)	which	 has	 been	 attributed	 to	 both	 the	 pro-inflammatory	
nature	of	prolactin	(45).	However,	the	role	of	breastfeeding	in	the	development	and	
progression	 of	 RA	 continues	 to	 be	 contentious,	 with	 two	 more	 recent	 studies	
identifying	 a	 protective	 effect	 (46,47).	 Most	 recently,	 increased	 	 prolactin	 receptor	
expression	has	been	identified	in	macrophages	in	synovial	tissue	of	patients	with	RA	
and	psoriatic	 arthritis	 compared	with	 controls	 suggesting	a	possible	mechanism	by	









The	 strongest	 environmental	 association	with	 RA	 remains	 tobacco	 smoking,	which	
may	cause	up	to	35%	of	the	risk	in	seropositive	RA	(49).	It	has	been	implicated	in	both	
the	 pathogenesis	 of	 the	 disease,	 and	more	 aggressive	 erosive	 forms	 of	 the	 disease	
through	 the	promotion	or	production	of	ACPA	 (50).	 Smoking	 is	 strongly	 associated	
with	 the	development	of	 seropositive	 (specifically	ACPA	positive)	RA	 in	 individuals	
with	the	HLA-DRB1	shared	epitope	(51),	and	a	recent	meta-analysis	has	shown	that	
current	 smokers	 have	 a	 significantly	 increased	 risk	 of	 developing	 seropositive	 RA	
compared	to	non-smokers	(OR	1.64).	This	risk	is	exacerbated	in	males	where	the	risk	
is	 increased	 to	 nearly	 four-fold	 	 (OR	 3.91)	 (52).	 It	 is	 thought	 that	 smoking	 causes	
cellular	 stress	 in	 the	 lung	parenchyma	 leading	 to	 the	 activation	 of	 peptidylarginine	
deiminase	 enzymes	 (PADs)	which	 lead	 to	 the	 substitution	 of	 arginine	 for	 citrulline	
amino	acids.	Such	citrullination	of	self-peptides	is	thought	to	interact	strongly	with	the	
peptide	binding	groove	of	the	HLA-DRb1	protein,	particularly	in	individuals	with	the	
shared	epitope.	The	binding	of	 self-peptides	 to	 the	peptide	binding	groove	 leads	 to	






Periodontitis	has	been	associated	with	 an	 increased	prevalence	of	RA	 (55),	 and	RA	
patients	with	 severe	periodontitis	 have	been	 shown	 to	have	higher	disease	 activity	
score	of	28	joints	(DAS28)	when	compared	to	RA	patients	who	have	no	or	moderate	
periodontitis	 (56).	 The	 putative	 mechanism	 by	 which	 periodontitis	 might	 be	
associated	 with	 RA	 is	 through	 the	 observation	 that	 dental	 infections	 with	
Porphyromonas	 gingivalis	 (P.	 gingivalis)	 are	 associated	 with	 increased	 levels	 of	






these	 ACPAs	 then	 act	 systemically	 to	 break	 immune	 tolerance	 and	 invoke	 an	
inflammatory	arthritis	in	a	similar	manner	to	that	proposed	for	smoking	(Chapter	1;	
1.3.3.1),	 although	 no	 studies	 have	 demonstrated	 a	 clear	 cause/effect	 relationship.		
However,	this	association	requires	further	investigation,	and	appears	to	be	less	clear-
cut	than	that	identified	for	smoking,	with	a	recent	meta-analysis	identifying	that	the	











Whilst	 associations	 between	 infective	 triggers	 and	 RA	 have	 been	 identified,	 and	
infection	with	many	of	the	postulated	agents	does	cause	arthralgia,	definitive	evidence	
	 41	
of	 causality	 is	 lacking.	 Reasons	 for	 such	 a	 lack	 of	 definitive	 proof	 of	 causality	 are	
multiple	(61).		The	relatively	late-onset	of	RA	in	life	means	that	there	is	a	long-exposure	
time	 to	many	 factors	 (infective	 and	 otherwise)	 that	 are	 challenging	 to	 identify	 and	
control	 for.	 Moreover,	 an	 extended	 pre-clinical	 phase	 of	 the	 disease	 before	 the	
appearance	of	overt	synovitis	has	been	acknowledged	by	the	observed	emergence	of	
positive	RF	and	ACPA	several	years	prior	to	diagnosis	(62).	Induction	of	inflammatory	
arthritis	 in	 animal	 models	 provides	 a	 limited	 approximation	 of	 human	 disease	
mechanisms	and	does	not	consider	the	complex	human	genetic	risk	factors	previously	

















Obesity	 is	 one	 of	 the	 greatest	 public	 health	 challenges	 affecting	 many	 Western	
countries,	 and	 is	 increasingly	 being	 identified	 as	 having	 profound	 influence	 on	 the	
inflammatory	profile	of	individuals.	Adipose	tissue	has	a	diverse	range	of	actions	on	








the	 association	 between	 obesity	 and	 risk	 of	 developing	 RA,	 many	 studies	 have	
examined	how	increased	body	mass	influences	outcomes	in	RA,	and	there	appears	to	



















rates	 globally	 (particularly	 between	 southern	 European	 and	 northern	







generations	 were	 deemed	 less	 likely	 to	 develop	 RA	 (possibly	 by	 a	 reduction	 in	
exposure	to	a	precipitant	of	the	condition),	with	a	resultant	increase	in	age-of-onset	of	
the	 condition,	 as	 members	 of	 earlier	 birth	 cohorts	 have	 relative	 greater	 risk	 of	
developing	the	condition.	The	study	of	the	Olmstead	County	population	in	Minnesota,	
USA	 had	 noted	 a	 consistent	 decade-by-decade	 decrease	 in	 incidence	 of	 RA	 from	
61.2/100,000	population	in	1955	to	32.7/100,000	population	in	1995	(72).	However,	
the	 latest	 update	 to	 the	 analysis	 of	 this	 population	 has	 identified	 an	 increase	 in	
incidence	 for	 the	 first	 time	 in	 50	 years	 to	 40.9/100,000	 population,	 driven	 by	 a	










Such	 conflicting	 findings	 suggest	 multiple	 factors	 at	 play,	 including	 changing	 life-
expectancies,	 and	 environmental	 exposures,	 as	 well	 as	 better	 identification,	
characterisation	and	treatment	of	the	disease.		
	




the	small	 joints	 in	 the	hands	and	 feet	 -	usually	 the	metacarpophalangeal	(MCP)	and	






Symptoms	 typically	 comprise	 pain,	 stiffness	 and	 swelling	 at	 the	 affected	 joints.	 A	
characteristic	diurnal	variation	to	symptoms,	with	pain	and	stiffness	being	worse	in	
the	 morning,	 before	 easing	 off	 during	 the	 middle	 portion	 of	 the	 day,	 and	 often	
worsening	towards	the	latter	part	of	the	day	is	typical.	Movement	of	the	affected	joints	
usually	eases	symptoms	of	stiffness,	and	prolonged	periods	of	inactivity	often	causes	
symptoms	to	worsen.	 If	 left	untreated,	 the	 inflammatory	attack	on	the	 joints	causes	








poorly	 addressed	 by	 clinicians	 (76).	 Often,	 with	 appropriate	 suppression	 of	
inflammation,	 fatigue	 can	 improve.	 However,	 fatigue	 often	 persists	 despite	
achievement	of	optimal	outcomes,	such	as	remission	(77).		
	
Numerous	 different	 factors	 are	 thought	 to	 contribute	 to	 the	 development	 and	









low	 mood,	 although	 fatigue	 itself	 is	 noted	 to	 cause	 depression,	 so	 identifying	 the	
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direction	 of	 causality	 is	 difficult	 (79).	 Poor	 psychological	 coping	 strategies,	 learned	
helplessness,	difficult	 social	 circumstances	and	relationship	difficulties	have	all	 also	
been	associated	with	the	level	of	fatigue	experienced	by	RA	patients	(79,81).	
	
Reduced	 physical	 activity	 levels	 are	 also	 associated	 with	 fatigue,	 and	 exercise	
programmes	have	been	noted	to	improve	fatigue	in	RA	patients.	Obesity	also	appears	
to	be	associated	with	 increased	 levels	of	 fatigue,	although	whether	this	 is	acting	via	




One	of	 the	most	basic	challenges	 in	understanding	 fatigue	 is	effectively	and	reliably	
quantifying	 it	 (82).	 Currently	 many	 different	 scoring	 tools	 are	 available,	 which	 all	
assess	 fatigue	 in	different	ways	 (e.g.	 impact	 of	 fatigue	on	 ability	 to	do	 tasks,	mood,	
absence	 of	 fatigue),	 as	 well	 as	 using	 different	 mechanisms	 for	 quantifying	 effect	






































Higher	 cortical	 function	 is	 also	 essential	 in	 modulating	 the	 perception	 of	 pain.	
Activation	of	spinothalamic	tracts	in	chronic	pain	can	activate	the	sensory	cortex	and	
thalamus	 as	 well	 as	 the	 limbic	 system	 –	 leading	 to	 disruption	 of	 sleep,	 and	mood.	
Furthermore,	 individuals	with	 concurrent	 or	 past	 depression	 appear	 to	 have	more	
ready	activation	of	descending	pain	pathways.	Because	painful	stimuli	are	unpleasant,	
individuals	with	chronic	pain	have	higher	rates	of	depression,	which	in	turn	can	affect	




Because	 of	 these	 complex	 interactions,	 treatment	 of	 pain	 in	 RA	 is	 one	 of	 the	most	
challenging	aspects	of	management.	Treatment	of	RA	pain	needs	to	be	targeted	at	both	
abrogating	 the	 inflammatory	 component	 of	 pain,	 as	 well	 as	 providing	 appropriate	
	 47	
symptom	control	for	both	peripheral	and	central	neurological	aspects	of	chronic	pain.	
The	multifaceted	 nature	 of	 pain	 in	 RA,	makes	 symptom	 quantification	 challenging,	
particularly	 when	 assessing	 disease	 activity	 of	 RA.	 Composite	measures	 of	 disease	
activity	(such	as	the	DAS28	and	simplified	disease	activity	index;	SDAI)	incorporate	the	
quantification	of	pain	 into	the	respective	scores	using	a	single	visual	analogue	scale	
(VAS).	 Tender	 and	 swollen	 joint	 counts,	 as	 well	 as	 an	 inflammatory	 marker	 (the	
erythrocyte	 sedimentation	 rate	 (ESR)	or	CRP)	are	used	 to	attempt	 to	provide	more	




aspects	 conspire	 to	make	 the	 clinical	 assessment	 of	 active	 (inflammatory)	 RA	 very	
challenging.	Understanding	the	degree	to	which	inflammation	is	causing	symptoms	is	
essential	in	the	management	of	RA,	as	it	suggests	that	further	immunomodulation	may	





degree	 to	which	active	 inflammation	 is	playing	a	part	 in	 causing	pain,	 compared	 to	
existing	 joint	 damage	 or	 altered	 pain	 perception.	 Disease	 activity	 scores	 are	 the	
mainstay	 of	 clinical	 assessment	 of	 drug	 efficacy	 in	 RA,	 and	 such	 difficulties	 have	 a	
significant	 impact	 of	 the	 ability	 to	 assess	 the	 true	 impact	 and	 efficacy	 of	 a	 disease	
modifying	 drug	 in	 RA.	 These	 considerations	 are	 of	 great	 relevance	 to	 the	 work	














various	 carpal	 joints	 in	 the	 wrist.	 In	 the	 feet,	 the	 MTP	 joints	 are	 most	 commonly	
affected	(91).	Inflammation	at	these	joints	can	cause	the	plantar	fat	pads	to	move,	with	






increase	as	more	 inflammatory	cells	 infiltrate	 the	synovium,	and	 increased	vascular	
permeability	and	blood	flow	cause	extravasation	of	fluid	which	causes	further	swelling	




capsule	 and	 peri-articular	 ligaments	 occurs	 and	 allows	 the	 joints	 to	 assume	
characteristic	 deformities	 defined	 by	 competing	 mechanical	 forces	 in	 play	 around	
affected	joint	groups.		
	
Within	 the	hands,	 a	number	of	deformities	occur	 including	volar	 subluxation	of	 the	
radiocarpal	 joint	(resulting	 in	guttering	of	 the	extensor	tendons),	subluxation	of	 the	
ulnar	 styloid	 (causing	 a	 ‘piano	key’	 deformity),	 ulnar	drift	 at	 the	MCP	 joints	 causes	
imbalance	of	 forces	between	 the	 flexor	 and	 extensor	 tendons	of	 the	hands	 and	 can	

























nerves	which	 can	 lead	 to	 referred	 occipital	 pain.	 Alternatively,	 if	 the	 spinal	 cord	 is	




which	 prevents	 the	 odontoid	 peg	 from	 compressing	 the	 spinal	 cord.	 Symptoms	 of	
instability	at	the	atlanto-axial	joint	include	localised	tenderness,	referred	occipital	pain	
and	 upper	 limb	 neurological	 signs	 (brisk	 reflexes,	 dermatomal	 tingling	 sensations,	













most	 common	 extra-articular	 manifestations	 of	 RA	 is	 the	 formation	 of	 nodules.	
Associated	with	RF-	and	ACPA-	seropositive	RA,	nodules	can	occur	almost	anywhere	in	
the	body.	The	most	common	sites	for	nodule	formation	are	on	the	fingers	and	elbows,	
however,	 they	 can	also	occur	 in	 the	 lungs.	Rheumatoid	nodules	 in	 the	 lungs	 can	be	
indistinguishable	 from	 malignancy	 on	 most	 imaging,	 and	 may	 only	 be	 confidently	
diagnosed	 on	 biopsy.	 Rheumatoid	 nodules	 are	 usually	 not	 harmful	 in	 themselves,	




mortality.	 Chronic	 inflammation	 leads	 to	 accelerated	 atherosclerosis	 and	 increased	
risk	of	myocardial	infarction	and	death	compared	with	general	population	rates	(92-





mortality.	 Inflammatory	 attack	 on	 the	 lungs	 can	 cause	 pulmonary	 fibrosis,	 most	
commonly	 usual	 interstitial	 pneumonia	 (UIP)	 with	 honeycombing	 and	 traction	









earlier	 treatment	 and	 improving	 therapies,	 extra-articular	 manifestations	 are	
becoming	increasingly	uncommon	(91).	
	
1.5 Imaging in RA 
	
The	use	of	 imaging	 in	 the	diagnosis	and	management	of	RA	 is	 increasing	as	 further	





Plain	 film	 x-rays	 remain	 the	 main	 imaging	 technique	 used	 in	 the	 diagnosis	 and	
management	of	RA.	The	plain	film	changes	associated	with	RA	are	well	described	and	
typically	comprise	of	peri-articular	erosions,	joint	space	narrowing,	and	periarticular	
osteopenia.	 Soft-tissue	 swelling	 can	 be	 also	 identified,	 but	 typically	 only	 significant	
swelling	can	be	identified	(97).			
	
Despite	 being	 the	 oldest	 imaging	 technique,	 x-rays	 have	 a	 number	 of	 significant	
advantages	 over	 more	 recent	 imaging	 modalities.	 X-rays	 are	 cheap	 and	 quick	 to	
undertake	and	have	relatively	little	radiation	exposure	to	the	patient.	With	digitisation,	



















images	 less	 reliable	 for	 longitudinal	 assessment	 of	 joint	 changes	 for	 clinical	 and	
research	purposes.			
	





















1.6 Classification criteria for RA 
	
The	 first	 classification	 criteria	 for	 RA	 were	 defined	 by	 the	 American	 Rheumatism	
Association	(ARA;	subsequently	the	American	College	of	Rheumatology;	ACR)	in	1956	
and	revised	in	1958.	These	criteria	contained	eleven	criteria	which	included	clinical	
(joint	 pain,	 morning	 stiffness,	 joint	 swelling,	 symmetry	 of	 swelling,	 rheumatoid	
nodules),	laboratory	(serum	RF,	synovial	biopsy	and	nodule	biopsy)	and	radiographic	
criteria	 (plain	 film	 evidence	 of	 RA	 e.g.	 erosions).	 In	 1966,	 simplified	 classification	























1.	Morning	stiffness	 Morning	 stiffness	 in	 and	 around	 the	









3.	Arthritis	of	hand	joints	 At	 least	 one	 area	 swollen	 (as	 defined	
above)	in	a	wrist,	MCP,	or	PIP	joint	




MTPs	 is	 acceptable	 without	 absolute	
symmetry)	
5.	Rheumatoid	nodules	 Subcutaneous	 nodules,	 over	 bony	
prominences,	or	extensor	surfaces,	or	in	
juxta-articular	 regions,	 observed	 by	 a	
physician	




7.	Radiographic	changes	 Radiographic	 changes	 typical	 of	 RA	 on	
posteroanterior	 hand	 and	 wrist	
radiographs,	 which	 must	 include	
erosions	 or	 unequivocal	 bony	
decalcification	 localized	 in	 or	 most	
marked	 adjacent	 to	 the	 involved	 joints	




These	 criteria	were	updated	 in	 2010,	when	 a	 combined	ACR/EULAR	 taskforce	was	
formed	 to	make	 classification	 criteria	more	 applicable	 to	 earlier	 onset	 disease	 (i.e.	
before	 radiographic	 and	 nodular	 changes)	 in	 line	 with	 the	 changes	 in	 treatment	
paradigms	since	1987	(101).	The	score	was	designed	to	be	used	in	patients	who	have	

































includes	 genetic	 risk	 factors	 (phase	 A),	 environmental	 (phase	 B)	 and	 systemic	














Prior	 to	 1899,	 there	 were	 very	 limited	 treatments	 for	 RA.	 Thomas	 Sydenham	
recommended	 extended	 bloodletting,	 purgatives	 and	 dietary	 restrictions	 (12)	 and	
willow	 or	 poplar	 bark	 have	 been	 used	 since	 ancient	 Greek	 times	 (subsequently	














The	active	component	of	aspirin	 is	salicyclic	acid	and	 its	anti-inflammatory	effect	 is	
mediated	 through	 its	 ability	 to	 prevent	 the	 formation	 of	 prostaglandins	 and	
thromboxanes	via	the	cyclooxygenase	1	and	2	pathways.	Whilst	the	anti-inflammatory	
effect	can	be	efficacious	in	reducing	symptoms	related	to	RA,	it	does	not	modulate	the	



























to	 temporarily	 improve	 the	 symptoms	 of	 RA.	 This	 lead	 Hensch	 to	 develop	 the	







physicians	meeting	 in	 1949,	 the	 results	 of	 the	 trial	 became	widely	 publicised,	with	





much	 as	 possible,	 to	 short-term	 therapy	 while	 establishing	 longer	 term	 disease	
modifying	therapy,	or	as	short	term	flare	management	(19).	
	
The	 anti-inflammatory	 effect	 of	 corticosteroids	 acts	 by	 binding	 with	 intracellular	
glucocorticoid	 receptors	within	 the	 cytoplasm	of	 cells.	Binding	of	 corticosteroids	 to	









anti-cancer	 drug	 in	 a	 condition	 regarded	 as	 ‘benign’	 (115).	 Additionally,	 steroid	
treatments	 were	 seen	 as	 so	 efficacious	 (and	 the	 risk	 of	 long-term	 corticosteroid	
therapy	had	yet	to	be	identified),	there	was	little	appetite	for	using	a	potentially	risky	
anti-cancer	drug	in	treating	rheumatoid.	However,	use	of	methotrexate	became	more	
widespread	 following	randomised	controlled	clinical	 trials	 through	 the	1980s	(116-
119),	and	head-to-head	studies	 in	 the	1980s	and	1990s	(120-123),	 finally	replacing	






thought	 to	 be	 central	 to	 its	 disease	 modifying	 properties	 in	 RA.	 Methotrexate	
suppresses	T-cell	activation	as	well	as	down-regulating	B-cell	function	and	inhibiting	
the	 binding	 of	 IL1b	 to	 its	 receptor.	 It	 is	 also	 a	 potent	 inhibitor	 of	 dihydrofolate	
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reductase	 which	 catalyses	 the	 conversion	 of	 dihyrofolate	 to	 the	 active	 form,	
tetrahydrofolate.	Folic	acid	is	essential	in	the	production	of	the	nucleic	acid	thymidine,	
so	inhibition	of	this	impairs	DNA,	RNA	and	protein	synthesis.	Evidence	also	suggests	











(sulfapyridine	 and	 mesalazine).	 Sulfapyridine	 is	 then	 subsequently	 absorbed	
systemically,	while	the	majority	of	the	mesalazine	remains	in	the	colon.	In	vitro	studies	
have	 demonstrated	 suppression	 of	 expression	 of	 IL-1,	 IL-2,	 IL-6,	 IL-12	 and	 TNF,	
although	 exactly	 how	 sulfasalazine	 acts	 is	 unknown.	 Sulfasalazine	 also	 reduces	
synovial	 hyperplasia	 and	 chemotaxis	 of	 inflammatory	 cells	 to	 the	 joints.	 Numerous	
studies	have	shown	sulfasalazine	to	be	efficacious	as	a	disease	modifying	drug	in	RA,	
both	independently	and	in	combination	with	other	disease	modifying	anti-rheumatic	









the	 pH	 within	 lysosomes	 which	 reduces	 the	 efficacy	 of	 antigen	 presentation,	 and	
interferes	with	toll-like	receptors.	They	are	clinically	efficacious	in	RA,	although	their	
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In	 addition	 to	 the	 aforementioned	 drugs,	 other	 DMARDs	 have	 been	 used	 in	 the	
treatment	 of	 RA,	 including	 leflunomide,	 azathioprine,	 cyclosporine	 and	 others.	








As	 previously	 discussed	 (1.2),	 TNF	 plays	 a	 key	 role	 in	many	 of	 the	 key	 pathogenic	













improvement	 in	 their	 arthritis.	 Following	 the	 success	 of	 this	 initial	 trial,	 further	
investigations	were	undertaken,	resulting	in	a	multicentre	placebo-controlled,	double-
blind,	 randomised	 trial	 which	 demonstrated	 prolonged	 efficacy	 of	 treatment	 with	
repeated	administration	of	drug	(132).	The	demonstration	of	clinical	effectiveness	of	
anti-TNF	 blockade	 in	 RA	 led	 to	 rapid	 development	 of	 other	 monoclonal	 antibody	





exact	 reasons	 for	 non-response	 were	 not	 clear	 (29).	 In	 addition	 to	 variations	 in	
response,	the	potential	for	immunogenicity	by	anti-TNF	was	recognised,	and	high	anti-





As	 further	 advances	 in	 understanding	 of	 RA	 have	 identified	 other	 key	 cytokines	
involved	 in	 the	pathogenesis	of	RA,	additional	 targeted	monoclonal	antibodies	have	
been	developed,	including	anti-IL6,	anti-CD20	and	more	recently,	anti-IL17.			
	
1.8  Evolution of treatment paradigms for RA 
	
With	 the	 increasing	 array	 of	 effective	 disease	 modifying	 treatments	 for	 RA,	 and	 a	
greater	understanding	of	the	epidemiology,	immunopathology	and	progression	of	the	








the	 COBRA	 (137),	 BeST	 (138)	 and	 TICORA	 studies	 (125),	 demonstrated	 superior	
outcomes	 to	 traditional	more	 cautious	dosing	 strategies,	 a	new	consensus	emerged	
amongst	 the	 rheumatology	 community	 of	 the	 importance	 of	 earlier	 diagnosis	 and	
instigation	 of	 disease	 modifying	 drugs,	 before	 joint	 damage	 was	 evident.	 With	 the	
wider	array	of	therapeutic	agents	available,	better	outcomes	for	more	patients	seemed	
more	 attainable.	 The	 parallel	 development	 of	 widely	 accepted	 outcome	 measures	
(such	 as	 the	 DAS28;	 covered	 in	 more	 depth	 in	 Chapter	 2)	 also	 enabled	 treatment	
targets	 to	 become	more	 standardised,	 and	 allowed	 treatment	 goals	 to	 be	 set,	 with	
progress	 towards	 these	 goals	monitored	more	 easily.	With	 the	publication	updated	















DMARDs	 (one	 of	 which	 should	 be	 methotrexate)	 at	 the	 maximum	 tolerated	 dose.	











Whilst	 remission	 remains	 the	 target	 of	 treatment,	 most	 studies	 focus	 on	 the	
achievement	of	outcomes	at	a	predetermined	point	in	time,	often	at	6	or	12	months	
after	initiating	therapy.	This	is	understandable	as	it	fits	with	a	standard	clinical	trial	
design	paradigm	 for	 testing	a	priori	hypotheses.	However,	 the	outcomes	of	 trials	at	
such	 single	 time	points	do	not	 represent	 a	permanent	 state.	 Patients	 and	 clinicians	







given	 it	 necessitates	 following	 up	 patients	 until	 death.	 Deciding	 the	 duration	 of	
sustained	 remission	 also	 requires	 decisions	 to	 be	 made	 on	 the	 frequency	 of	



















activity	 and	 sustained	 remission	 to	 be	 undertaken.	 The	 register	 (including	 the	
background	to	its	inception	and	methods)	is	described	in	more	detail	in	Chapter	3.	
	
1.9  Chapter summary 
	
The	diagnosis	and	management	of	RA	has	changed	remarkably	 in	a	 relatively	 short	
time.	In	the	space	of	100	years,	RA	has	evolved	from	being	a	condition	that	was	barely	
recognised	by	most	clinicians	with	no	effective	treatment	options;	to	being	a	condition	
with	 a	 panoply	 of	 treatment	 options;	 evidence–based	 national	 and	 international	
standards	 that	 recommend	 that	 clinicians	 identify	 the	 condition	 and	 commence	
disease	modifying	treatments	within	three	months,	aiming	for	complete	elimination	of	
symptoms.	However,	despite	excellent	progress,	not	every	patient	achieves	remission.	









biologics	 collected	 by	 the	 BSRBR-RA;	 anti-TNFs.	 It	 will	 explore	 how	 frequent	 and	
sustainable	optimal	outcomes	are	outside	of	the	clinical	trial	setting.	However,	as	with	










































The	 advance	 in	 available	 drugs	 and	 the	 treatment	 paradigms	 have	 dramatically	
improved	 outcomes	 in	 RA.	 However,	 whilst	 the	 cure	 remains	 elusive,	 remission	 is	
increasingly	becoming	attainable	for	an	increasing	proportion	of	patients	with	RA.	To	
begin	 to	understand	what	 remission	 is,	 it	 is	helpful	 to	 return	 to	 the	Oxford	English	
Dictionary	(1),	where	the	definition	of	remission	in	a	medical	context	is	defined	as	the:	
	




At	 first	glance,	 such	a	definition	of	 remission	appears	 to	delineate	a	clear	state	 that	
could	be	identified	and	applied	to	RA.	However,	on	closer	inspection,	the	definition	of	
remission	begins	to	lay	out	the	many	difficulties	in	both	achieving	and	identifying	such	
a	 state.	 A	myriad	 of	 questions	 arises	 including:	 How	 to	 identify	 the	 severity	 of	 the	
disease	 or	 symptoms?	 Is	 severe	 disease	 one	 that	 causes	 disability,	 joint	 pain	 or	





















2.1 Measuring disease activty – the development of composite 





disease	 activity	 index	 included	 the	 Ritchie	 Articular	 Index	 (RAI)	 (144)	 in	 1968.	
However,	 this	 only	 measured	 joint	 pain	 and	 did	 not	 assess	 joint	 swelling	 or	
inflammation,	 both	hallmark	 features	 of	RA.	Whilst	 intra-rater	 reliability	was	 good,	
inter-rater	reliability	was	poor.	This	posed	problems	in	achieving	a	consistent	measure	
of	disease	activity,	not	only	in	clinical	practice,	but	also	in	clinical	trials,	where	a	lack	of	




development	 of	 evidenced-based	 treatment,	 and	 in	 turn	 led	 to	 the	 formation	 of	 an	
international	group	of	rheumatologists	to	define	a	core	set	of	outcome	measures	to	be	
used	in	RA	clinical	trials,	subsequently	known	as	OMERACT.	In	1992,	the	first	meeting	












years,	 as	 limitations	 with	 the	 DAS28	 were	 identified,	 new	 composite	 scores	 were	
developed,	 including	 the	 SDAI	 (148)	 and	 the	 Clinical	 Disease	Activity	 Index	 (CDAI)	
(149).	Increasingly,	the	evidence	base	for	fully	patient	reported	outcome	measures	has	









and	 laboratory	 assessment	 of	 RA	 disease	 activity	 into	 a	 single	 score.	 This	 involved	
combining	the	RAI	measurement	of	tenderness	in	44	joints,	with	an	assessment	of	joint	
swelling,	a	patient	global	assessment	of	health	and	an	inflammatory	marker	(the	ESR).	
To	 establish	 content	 validity	 of	 the	 score,	 analysis	 of	 clinical	 records	 was	 used;	 if	














The	 threshold	 for	 remission	 with	 the	 DAS	 was	 set	 at	 ≤1.6,	 corresponding	 to	 the	
attainment	of	the	ARA	1981	remission	criteria	(151)	(discussed	in	Chapter	2;	2.3.1),	
although	of	note,	no	 time	element	was	 specified	 in	 the	DAS	definition	of	 remission,	







assessed	 by	 the	 DAS.	 Whilst	 the	 DAS	 was	 a	 reproducible	 and	 valid	 score,	 the	
assessment	of	44	 joints	was	deemed	to	be	cumbersome	 in	clinical	practice	and	had	
limited	uptake	in	routine	practice.	In	addition,	instead	of	grading	tenderness	at	each	of	
the	 44	 included	 joints	 (between	 0	 –	 3),	 the	 DAS28	 opted	 for	 a	 binary	 assessment	
(yes/no)	of	 tenderness	 at	 each	 joint.	 	 The	 streamlining	of	 the	DAS	made	 the	 global	












































However,	 as	 treatment	 of	 RA	 became	 more	 successful	 (due	 to	 more	 aggressive	
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more	 stringent	 measure	 of	 disease	 activity,	 particularly	 at	 lower	 levels	 of	 disease	
activity,	 which	 were	 increasingly	 being	 achieved.	 Like	 the	 DAS28,	 it	 combined	 the	
domains	of	tender	and	swollen	joints	(using	the	assessment	of	the	same	28	joints	as	
the	DAS28),	a	patient	self-report	of	overall	disease	activity	(the	patient	global	health	
assessment;	 PGA)	 and	 an	 inflammatory	marker	 (the	 CRP).	 However,	 in	 addition	 to	
these,	a	physician	rating	of	disease	activity	was	included	to	encompass	a	physician’s	
general	 feeling	 of	 how	 active	 the	 disease	 was.	 These	 measures	 are	 simply	 added	





















the	 inflammatory	 marker	 parameter	 (CRP).	 Again,	 as	 with	 the	 SDAI	 no	 complex	





























































































































































































































































• P-DAS	 –	 the	 P-DAS	 incorporates	 the	 Stanford	 health	 assessment	 questionnaire	
(HAQ)	 questionnaire	 as	 well	 as	 a	 patient	 global	 assessment	 of	 disease	 activity.	
However,	 in	 contrast	 to	 the	 aforementioned	 patient	 reported	 disease	 activity	












2.3 Defining ‘remission’ in RA 
	
As	 outlined	 previously,	 the	 definition	 of	 remission	 requires	 focussing	 to	 be	 of	 any	
meaningful	use	in	the	context	of	RA.	The	first	effort	to	formally	define	remission	in	RA	
was	undertaken	 in	 the	 early	 1980’s	 (151).	 Subsequently	 developed	disease	 activity	
scores	 all	 had	 individual	 thresholds	 of	 disease	 activity	 that	 were	 identified	 as	
remission,	 although	 when	 comparing	 between	 disease	 activity	 scores,	 the	 level	 of	
disease	 activity	 required	 to	 meet	 the	 criteria	 of	 remission	 are	 different.	 The	
inconsistency	in	defining	remission	led	to	an	international	collaboration	between	the	

















The	 ACR/EULAR	 joint	 statement	 on	 remission	 (170)	 utilised	 a	 stringent	 Boolean	
criteria	 including;	 ≤1	 tender	 or	 swollen	 joint;	 CRP≤1	 mg/dl;	 and	 a	 patient	 visual	
analogue	score	of	≤1	on	a	0-10	scale;	or	an	SDAI	score	of	≤3.3.	No	longitudinal	time	
element	 was	 specified,	 and	 the	 ESR	 was	 replaced	 by	 the	 CRP	 as	 the	 measure	 of	
inflammation.	Due	to	the	issues	with	the	leniency	of	the	DAS28	definition	of	remission,	
this	was	not	included	in	the	ACR/EULAR	2011	criteria.	Whilst	the	ACR/EULAR	criteria	










(which	 disease	 modifying	 immunomodulatory	 treatments	 target)	 from	 the	 non-






individuals	 with	 RA	 is	 a	 likely	 result	 of	 an	 active	 inflammatory	 component	 of	 the	
disease.	In	this	situation,	targeting	inflammatory	disease	activity	should	reduce	pain,	
stiffness	 and	 fatigue.	 However,	 where	 there	 is	 a	 disconnect	 between	 inflammatory	
disease	 activity	 and	 an	 individual’s	 experience	 of	 pain,	 fatigue	 and	 stiffness,	












measures	 of	 inflammation	 (ESR	 and	 CRP),	 physician	 global	 scales,	 and	 objective	
measures	 of	 clinical	 inflammation	 (e.g.	 swollen	 joint	 count),	 as	 well	 as	 weighting	
different	aspect	of	the	components.	The	DAS28	in	particular	gives	greater	weight	to	the	
patient	reported	components	than	physician	or	laboratory	determined	measures	(such	
as	 the	 CRP	 or	 ESR).	 Research	 has	 also	 been	 undertaken	 on	 potential	 methods	 of	
delineating	 between	 inflammatory	 and	 non-inflammatory	 pain,	 as	 a	 method	 of	
identifying	which	patients	may	have	a	greater	or	lesser	chance	of	responding	to	disease	
modifying	treatment	such	as	anti-TNF.	Of	particular	note	is	work	by	Kristensen	et	al.	
(173)	 who	 identified	 that	 patients	 with	 a	 high	 swollen	 to	 tender	 joint	 count	 ratio	
(S:TJR)	were	2-	to	3-	times	more	likely	to	achieve	a	good	response	(defined	as	an	ACR50	





at	 least	 3	 of	 the	 following:	 the	 patient’s	 global	 assessment	 of	 disease	 status;	 the	 patient’s	 assessment	 of	 pain;	 the	 patient’s	
assessment	of	 function	(measured	using	 the	Stanford	Health	Assessment	Questionnaire);	 the	physician’s	global	assessment	of	
disease	status;	and	serum	C-reactive	protein	levels.	
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To	 further	 complicate	matters,	 there	 is	 evidence	 that	 synovitis	 can	 persist	 despite	









important	 considerations	 when	 understanding	 remission	 and	 predictors	 of	 such	 a	
clinical	state.	
	





for	 inclusion	 in	 the	 definition	was	 the	 patient	 global	 assessment	 of	 disease	 activity	
(PGA;	measured	by	the	VAS)	and	patient	reported	pain	(170).	Visual	analogue	scales	
encompass	 the	otherwise	unmeasurable	multiple	 facets	 of	 disease	 in	 a	 single	 scale.	
However,	 such	a	 tool	 is	a	blunt	one,	and	 	a	 recent	 international	qualitative	study	of	
remission	 in	 RA	 (172),	 demonstrated	 the	 extremely	 diverse	 patient	 perspective	 on	
what	remission	meant	 to	 them.	 Interestingly,	 the	 thematic	analysis	 split	 the	patient	
perspective	into	the	‘symptoms’	of	remission	(such	as	joint	pain	and	stiffness)	and	the	
‘impact’	 of	 remission	 on	 daily	 life	 (such	 as	 independence,	 ability	 to	 work	 and	
participate	in	family	life).	Analysis	highlighted	that	whilst	absence	of	symptoms	such	
as	joint	stiffness,	and	swelling	(the	focus	of	most	clinically	driven	outcome	measures)	
was	 of	 importance	 to	 patients,	 the	 ability	 to	 plan	 future	 events	 knowing	 the	 likely	



































as	 ‘sustained’	 in	 the	 context	 of	 a	 lifelong	 condition	 such	 as	 RA,	 selecting	 longer	
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durations	of	remission	presents	increasing	challenges	with	ever	decreasing	numbers	
of	 patients	 with	 sufficient	 data	 to	 classify	 having	 achieved	 increasingly	 stringent	
criteria.	
	
















































represent	 a	 clinical	 deterioration	 in	 disease	 activity,	 but	 by	 using	 disease	 activity	
thresholds	 to	 categorise	 scores,	 it	 would	 be	 recorded	 as	 so	 (a	 failure	 to	 maintain	
remission).	In	fact,	using	disease	activity	thresholds	in	this	circumstance	would	mean	
a	DAS28	score	of	2.61	is	classed	in	the	same	group	as	a	DAS28	score	of	3.2,	a	disease	
activity	 score	 that	 can	 only	 be	 achieved	 by	 substantial	 worsening	 of	 multiple	
components	of	the	disease	activity	score.		Therefore,	whilst	sustained	remission	is	the	
goal	 of	 treatment,	 and	 treat-to-target	 recommendations	 suggest	 modifying	 and	
escalating	 treatment	 until	 a	 state	 of	 remission	 is	 achieved	 (180),	 clinical	 treatment	
decisions	are	often	much	more	pragmatic	and	are	poorly	modelled	by	applying	strict	
disease	activity	thresholds.	Such	real-world	pragmatism	represents	a	challenge	when	




















each	 disease	 activity	 score	 in	 isolation.	 To	 model	 this	 situation	 more	 accurately,	
trajectory	mapping	considers	previous	and	subsequent	disease	activity	scores	when	
plotting	 an	 individual’s	 response	 to	 drug	 over	 time,	 and	 groups	 individuals	 into	
common	trajectories	of	response.	The	overall	trend	of	results	allows	for	‘blips’	in	scores	
or	isolated	disease	flares	that	may	cross	a	disease	activity	threshold.	Each	individual’s	




environment	 and	 to	 the	 individual	 patient.	 Such	 an	 approach	 has	 previously	 been	






aim	of	 identifying	 commonalties	 between	 individuals	within	 each	 group,	 as	well	 as	
differences	between	groups.	If	associations	between	clinical	or	demographic	features,	























least	 six	months	 before	 starting	 anti-TNF	 treatment.	 This	 practice	 differs	markedly	
from	many	other	European	and	North	American	practices,	where	access	to	anti-TNF	is	






















offered.	 In	 addition,	 if	 a	 patient	 has	 had	multiple	 failed	 trials	 of	 disease	modifying	
drugs,	they	may	resort	to	accepting	a	modest	response	from	a	drug,	rather	than	being	
appropriately	guided	 to	a	 treatment	 that	may	have	a	higher	 likelihood	of	 achieving	
remission.	
	





















Anti-TNF	 medications	 are	 the	 most	 frequently	 used	 biologic	 agents,	 and	 the	 work	
undertaken	 in	 this	 thesis	 aims	 to	 provide	 the	 evidence	 to	 enable	 personalised	
recommendations	for	anti-TNF	treatments.	Further	work	will	be	required	to	focus	on	
the	other	biologic	and	novel	synthetic	drugs.	Currently,	due	to	the	strong	evidence	of	
efficacy	 of	methotrexate	 in	 RA	 (183),	 coupled	with	 low	 cost,	 initial	 treatment	with	














working	 to	 capture	 the	 true	 picture	 of	 longitudinal	 response	 to	 treatments?	 	 Is	 it	
possible	 to	 identify	which	patient	 is	 likely	 to	 respond	optimally	 to	which	 treatment	
either	 prospectively	 or	 early	 in	 the	 initiation	 phase	 of	 treatment?	 These	 questions	
apply	 to	all	modalities	of	 treatments	and	outcome	measures,	but	 for	 this	 thesis,	 the	




















is	 essential	 to	 ensure	 that	 the	 subsequent	 analysis	 of	 factors	 associated	 with	
sustained	 remission	does	 not	 identify	 spurious	 associations,	 or	miss	 important	
associations,	due	to	inaccuracies	in	the	disease	activity	scoring	systems	used.			
	
3. To	 use	 the	 BSRBR-RA	 to	 investigate	 the	 predictors	 of	 sustained	 remission	 for	



























the	clinical	 treatment	 landscape	of	 in	 the	UK.	However,	 existing	 strategies	 for	post-
marketing	 surveillance	 of	 the	 drugs	 were	 identified	 to	 have	 significant	 limitations	
(185),	particularly	 for	rare	events	and	 those	with	a	 long	 latent	period	 that	may	not	
occur	 within	 the	 timeframe	 of	 an	 RCT	 (186).	 Because	 RCTs	 are	 powered	 to	
demonstrate	efficacy,	rather	than	potential	adverse	events,	the	required	sample	sizes,	
and	 trial	 durations	 are	 insufficient	 to	 examine	 questions	 about	 drug	 safety.	








4.2 Study design 
	




biologic	 agents	 was	 established	 in	 2012,	 and	 a	 specific	 register	 for	 patients	 with	
psoriatic	arthritis	is	currently	being	established.	After	the	foundation	of	the	ankylosing	





The	 initial	 study	 was	 powered	 to	 detect	 a	 two-fold	 rise	 in	 the	 risk	 of	 lymphoma	
following	 treatment	 with	 anti-TNF	 therapies	 compared	 to	 non-biologic	 treated	
patients,	 and	 it	 was	 calculated	 that	 20,000	 person-years	 of	 follow-up	 would	 be	
required	in	both	cohorts	to	identify	such	an	increase	with	a	power	of	80%.	This	equated	
to	approximately	4000	individuals	in	the	exposed	cohort	for	each	drug,	and	required	a	
similar	 number	 in	 the	 unexposed	 cohort,	 each	 followed	 for	 an	 average	 of	 5	 years.	
Because	 individuals	 with	 RA	 have	 an	 increased	 risk	 of	 infection	 and	 malignancy	











the	 cohort	 being	 closed	 at	 3771	 individuals	 in	 2009.	 New	 anti-TNFs	 and	 other	
	 91	
biological	agents	were	added	 to	 the	registry	as	 they	became	available.	Adalimumab	
(Humira™)	was	added	in	2002	and	target	recruitment	(n=4000)	was	achieved	by	2007.	
No	 new	 anti-TNF	 agents	were	 added	 to	 the	 registry	 until	 2010	when	 certolizumab	
pegol	 (Cimzia™)	 was	 added,	 and	 a	 new	 comparator	 anti-TNF	 cohort	 (comprising	

















Enbrel™	(etanercept)	 2001-2005	 RA	 4000	
Remicade™	(infliximab)	 2001-2007	 RA	 4000	
Humira™	(adalimumab)	 2003-2008	 RA	 4000	
Cimzia™	(certlizumab	pegol)	 2010	onwards	 RA	 2000	
Anti-TNF	comparator	cohort	 2012	onwards	 RA	 4000	
Remsima™	(infliximab)	 2015	onwards	 RA	 500	
Inflectra™	(infliximab)	 2015	onwards	 RA	 500	
Benepali™	(etanercept)	 2016	onwards	 RA	 2000	
Flixabi™	(infliximab)	 2016	onwards	 RA	 500	





Anti-CD19	 Mabthera™	(rituximab)	 2006-2011	 RA	 1100	
Anti-IL6	 RoActemra™	(tocilizumab)	 2011	onwards	 RA	 850+	
Table	4.	BSRBR-RA	recruitment	dates	and	target	cohort	sizes.		
	
4.3 Recruitment Centres 
	
Recruitment	to	the	BSRBR-RA	has	been	from	over	250	rheumatology	clinics	across	the	





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































interest	 (ESI).	 Adverse	 events	 can	 be	 reported	 between	 follow-up	 points	 by	 both	












the	 study	 has	 been	 extremely	 low	 (1.6%)	 and	 return	 of	 questionnaires	 by	 both	
consultants		and	patients	has	been	high	(88%	and	68%	respectively).		
	











members	of	 all	 three	national	 registers	 (the	BSRBR-RA,	 -AS	and	 -PsA)	as	well	 as	
representatives	of	the	BSR.	The	proposal	is	evaluated	for	its	scientific	rigour	and	to	
ensure	 that	 the	 data	 available	 from	 the	 register	 are	 sufficient	 to	 evaluate	 the	
proposed	hypothesis.		The	proposal	is	also	checked	against	ongoing	studies	to	avoid	
















and	can	be	accessed	by	 the	researcher	 locally	using	 the	University	networks;	or	
remotely,	using	a	secure	virtual	private	network	(VPN)	connection.		
	
2. Data	 can	 be	 transferred	 via	 the	 University	 of	 Manchester	 secure	 data	 transfer	
service	(ZendTo™)	as	a	password-protected	and	encrypted	zip	file.	The	researcher	
is	 contacted	prior	 to	upload	of	 the	 file	 to	 confirm	 the	provided	email	 address	 is	
correct	 and	 to	 provide	 a	 secondary	 email	 address.	 The	 requested	 datafile	 is	














different	 biologic	 agents.	 The	 analyses	 in	 this	 thesis	 have	 focussed	 on	 two	 distinct	
cohorts	–	patients	with	paired	ESR	and	CRP	data,	including	all	biologic-treated	patients	
(except	Ro-Actemra™-	 treated	patients	 (Chapter	 8),	 and	patients	 starting	 their	 first	





Because	 the	 live	 BSRBR-RA	 database	 is	 continually	 being	 updated	 with	 new	




been	 validated.	 However,	 it	 is	 important	 that	 analyses	 occur	 using	 the	 most	
contemporaneous	 and	 complete	 dataset	 possible.	 To	 balance	 these	 two	 needs,	
static	datafiles	that	have	been	cross-checked	and	cleaned	are	extracted	from	the	
live	BSRBR-RA	database	on	a	six-monthly	basis.	This	allows	researchers	to	access	
to	 data	 that	 is	 both	 contemporaneous,	 and	 cross-checked	 with	 minimal	 data	



















RCT,	 causality	 cannot	 be	 attributed	 to	 any	 associations	 identified.	 This	 is	 because,	




RA	was	 designed	 originally	 for	 establishing	 long-term	 drug	 safety,	 not	 establishing	
drug	efficacy.	Therefore,	certain	aspects	of	 the	study	design	may	not	be	optimal	 for	
specifically	 examining	 longitudinal	 drug	 response	 profiles.	 For	 example,	 it	 may	 be	
interesting	to	examine	exactly	how	early	onset	of	response	is	for	anti-TNF.	However,	
with	data	collection	points	at	baseline	and	six	months,	it	is	not	possible	to	conclusively	














RCTs	 are	 the	 gold-standard	method	 for	 establishing	 a	 cause-effect	 relationship,	 the	
inclusion	 and	 exclusion	 criteria	 of	 such	 studies	 create	 a	 homogeneous	 population,	
which	are	not	representative	of	the	real-world	population	in	which	the	drug	is	used.	
Follow-up	protocols	of	RCTs	are	also	unrepresentative	of	routine	clinical	practice,	and	





give	 useful	 insights	 into	 real-world	 efficacy	 of	 the	 drug.	 They	 are	much	 less	 labour	
intensive	 for	 clinicians	 to	 recruit	 to	 and	 data	 are	 collected	 from	 routine	 practice.	
Because	 the	 BSRBR-RA	 has	 been	 ongoing	 for	 over	 15	 years,	 it	 is	 also	 possible	 to	
examine	the	evolution	of	clinical	practice,	and	how	the	demographics	of	the	patients	
using	 the	 drug	 have	 changed	 over	 time.	 The	 long-duration	 of	 follow-up	 enables	
investigation	of	outcomes	(such	as	the	long-term	durability	of	response)	that	would	
not	be	possible	in	most	RCTs.	In	addition,	because	the	BSRBR-RA	has	recruited	patients	












































Missing	 data	 are	 a	 feature	 in	 almost	 all	 datasets	 and	 their	 identification	 and	








There	 are	 no	definitive	 statistical	 tests	 that	 can	 ‘prove’	 any	particular	missing	data	
pattern,	so	categorisation	of	 the	missing	data	should	be	undertaken	by	examination	





As	 the	 name	 implies,	 MCAR	 occurs	 when	 missing	 data	 points	 occur	 completely	 at	
random	 through	 a	 dataset.	Missing	 data	 points	 have	 no	 relation	 to	 each	 other,	 the	
intervention	or	outcome.	If	missing	data	are	present	MCAR	is	optimal,	as	management	
of	 such	 missing	 data	 are	 least	 likely	 to	 introduce	 bias.	 Most	 imputation	 methods	
assume	 MCAR	 or	 MAR.	 In	 reality,	 MCAR	 very	 rarely	 happens	 in	 epidemiological	
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data	 points	 and	 complete	 data	 records.	 Therefore,	 in	 this	 situation,	 to	 satisfy	 the	
assumption	of	MCAR,	the	null	hypothesis	should	not	be	disproved.	This	method	has	
significant	 problems	 which	 are	 described	 in	 depth	 by	 Little	 (190),	 however	 the	
fundamental	problem	with	such	an	approach	is	that	a	separate	t-test	is	required	for	




is	 no	 significant	 difference	 between	 the	 missing	 data	 variables	 and	 the	 available	

















data	 is	 now	 related	 to	 the	 actual	 value	 of	 the	 data	 and	 are	MNAR.	 	 The	 distinction	
between	 MAR	 and	 MNAR	 is	 important	 because	 most	 imputation	 of	 missing	 data	










accuracy	 and	 power	 of	 the	 findings	 if	 data	 are	 inappropriately	 imputed	 or	 deleted	
respectively.	 There	 are	 numerous	 methods	 for	 managing	 missing	 data.	 The	 most	
commonly	used	methods	include:	complete-case	analysis/list-wise	deletion;	separate	




















method	 maintains	 the	 precision	 of	 analysis,	 but	 still	 does	 not	 adjust	 for	 possible	
selection	bias	if	there	is	a	reason	for	“missingness”	or	data	are	MNAR.	It	also	can	lead	
to	 difficulties	 with	 continuous	 variables,	 whereby	 inclusion	 of	 a	 ‘NA’	 or	 ‘missing’	



























data,	 the	 nearest	 neighbouring	 value	 can	 be	 used,	 or	 it	 can	 be	 based	 on	 other	
parameters	that	try	match	the	donor	value	to	the	missing	data	record	value	(192).	All	




to	 complete	 any	 missing	 data	 points.	 However,	 mean	 imputation	 causes	 auto-












the	 reasons	 for	 the	 limited	 use	 of	 this	 method	 previously	 was	 that	 it	 required	 a	
	 107	
significant	 amount	 of	 computational	 power	 to	 undertake.	 However,	 with	 the	 rapid	
increase	in	processing	power	available,	this	method	can	now	be	used	for	most	datasets	
using	 standard	 personal	 computers.	 There	 are	 two	 main	 methods	 of	 multiple	
imputation	 -	multiple	 imputation	using	 chained	equations	 (MICE),	 and	expectation-
maximisation	and	bootstrapping	 (EMB)	algorithms.	MICE	algorithms	use	a	Markov-
chain	 Monte-Carlo	 (MCMC)	 method	 of	 simulating	 a	 dataset	 many	 times	 (usually	
thousands)	 with	 random	 numbers	 being	 selected	 for	missing	 data	 points.	 After	 an	
initial	‘burn-in’	period	(usually	a	few	thousand	simulations),	the	law	of	large	numbers	
(193,194)	 means	 that	 values	 converge	 towards	 plausible	 ones	 and	 can	 be	 used	 to	
complete	 the	 missing	 data	 points.	 To	 ensure	 an	 accurate	 understanding	 of	 the	
uncertainty	in	the	imputed	data,	multiple	imputed	datasets	should	be	created	(often	
five,	but	occasionally	more)	and	Rubin’s	rules	(Chapter	5;	5.1.5.1)	used	to	accurately	
quantify	 uncertainty	 in	 estimates.	 However,	 because	 MICE	 requires	 thousands	 of	
simulations	 for	 each	 variable	 with	 missing	 data	 it	 becomes	 increasingly	










data	(as	described	 in	Chapter	5;	5.1.3).	The	other	assumption	 is	 that	 the	data	(both	
missing	 and	 present)	 have	 a	 multivariate	 normal	 distribution,	 however	 there	 is	
evidence	that	Amelia	works	adequately	for	categorical	as	well	as	mixed	datasets	(195).	
Using	 the	 MAR	 assumption,	 Amelia	 identifies	 relationships	 between	 the	 variables	
included	within	the	model	and	uses	Bayesian	inference	to	bootstrap	parameters	and	





and	 the	 relationship	 between	 the	 height	 values	 and	 weight	 data	 to	 inform	 the	
parameters	around	each	missing	data	point.	This	would	mean	that	if	an	individual	with	
a	 missing	 height	 data	 point	 weighed	 100kg,	 Amelia	 would	 apply	 a	 different	 set	 of	
parameters	than	an	individual	who	weighed	50kg	who	might	also	have	missing	height	
data.	This	is	a	particularly	useful	feature	considering	the	analysis	of	outcomes	in	the	


















As	 a	 default,	 Amelia	 generates	 five	 imputed	 datasets	 (although	 greater	 or	 fewer	












Rubin’s	 rules	 form	 the	 foundation	 on	 which	 multiple	 imputation	 analysis	 can	 be	
undertaken	(197).	When	undertaking	statistical	analysis	on	multiply	imputed	datasets,	
it	 is	 important	 to	undertake	 the	proposed	analysis	on	each	of	 the	 imputed	datasets	
























The	 between-dataset	 imputation	 variance	 (B)	 is	 then	 calculated	 by	 calculating	 the	






























because	 the	 disease	 duration	 is	 calculated	 by	 subtracting	 ‘the	 year	 of	 starting	 on	 a	
biologic’	from	the	‘year	of	diagnosis’.	Because	the	two	variables	are	imputed	separately	
and	 disease	 duration	 calculated	 after	 imputation,	 in	 a	 small	 number	 of	 cases,	 the	
imputed	value	for	year	of	diagnosis	is	greater	than	the	year	of	biologic	date,	leading	to	
a	negative	value.	Similar	occurrences	can	occur	with	‘age	at	diagnosis’	and	‘age	when	






of	 diagnosis	 for	 some	 data,	 but	 not	 others.	 This	 generates	 greater	 problems	 as	 it	
asymmetrically	alters	relationships	within	the	dataset.		It	is	also	important	to	note	that	
with	 multiple	 imputation,	 results	 are	 not	 reported	 from	 each	 individual	 imputed	
dataset,	so	individual	implausible	data	are	less	directly	relevant	to	the	overall	results.	
Instead,	the	multiple	datasets	are	used	to	simulate	variance	and	uncertainties	in	the	
imputed	 data	 and	 the	 individual	 values	 are	 used	 to	 generate	 composite	 estimates.	
Therefore,	 these	 implausible	 values	 contribute	 to	 the	 estimates	 of	 uncertainty	
quantified	by	the	variance.	In	this	analysis,	five	imputed	baseline	datasets	are	created	
and	five	imputed	longitudinal	datasets,	meaning	that	a	total	of	25	datasets	are	created	
when	 combined.	 Analysis	 is	 then	 undertaken	 on	 all	 25	 datasets	 and	 estimates	 are	
combined	using	Zelig	software.	Manually	altering	the	imputed	data	would	impact	on	
the	quantification	of	uncertainty	in	the	final	estimate,	and	is	less	desirable	than	the	few	
implausible	 results	 that	 may	 be	 occur	 otherwise.	 Therefore,	 in	 this	 analysis,	
implausible	values	post	imputation	have	not	been	individually	altered.	
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between	 different	 versions	 of	 the	 DAS28.	 Inter-score	 comparison	 requires	 use	 of	
specific	statistical	methods	for	continuous	and	categorical	scores.	Because	the	DAS28	







Bland-Altman	 plots	 and	 statistics	 are	 a	 validated	 measure	 of	 visualising	 and	
quantifying	 agreement	 between	 two	 measures	 that	 have	 a	 continuous	 scale	 (198).	
Whilst	plotting	the	values	of	one	version	of	the	DAS28	against	another	can	demonstrate	
correlation	 between	 the	 two	 scores,	 it	 is	 important	 to	 note	 that	 this	 does	 not	
demonstrate	 agreement.	 Intraclass	 correlation	 (ICC)	 statistics	 are	 used	 when	
comparisons	are	made	using	the	same	score	(i.e.	two	observers	scoring	an	x-ray	for	RA	
disease	progression	using	the	same	score),	however,	if	an	inconsistent	score	is	used,	






𝑦 − 𝑎𝑥𝑖𝑠	𝑣𝑎𝑙𝑢𝑒𝑠 = 𝐴 − 𝐵	









with	 the	 size	 of	 the	 measurement.	 If	 the	 discrepancy	 between	 the	 two	 scores	 is	









The	 continuous	 version	 of	 the	 DAS28	 can	 also	 be	 categorised	 into	
remission/LDA/MDA/HDA.	 To	 compare	 agreement	 between	 the	 categorical	
transformations	of	the	different	versions	of	the	DAS28,	agreement	matrices	are	used	
(Figure	 4).	 	 Such	 matrices	 allow	 comparison	 of	 how	 the	 two	 scores	 agree	 when	
identical	disease	activity	thresholds	are	applied	to	each	score.	They	are	also	useful	for	





























The	 maximum	 possible	 value	 that	 k	 can	 take	 is	 +1	 which	 indicates	 near-perfect	






the	 DAS28	 analysis,	 the	 assumption	 of	 independence	 is	 reasonable.	 Although	 the	
tender	 joint	 count,	 swollen	 joint	 count	 and	 PGA	 are	 shared	 between	 the	 different	
versions	of	the	score,	the	inflammatory	markers	(CRP	and	ESR)	are	independent.		In	
addition,	the	equations	to	calculate	the	final	DAS28	score	are	different.	Therefore,	the	




















magnitude	 of	 disagreement	 when	 it	 occurs.	 For	 example,	 a	 reference	 (𝑦E)	 and	
comparator	(𝑦E^)	score	may	have	almost	perfect	agreement,	but	when	the	two	scores	
do	not	agree,	they	may	be	slightly	different	or	substantially	different	(i.e.	when	the	two	
















For	 each	 individual,	 this	 involves	 subtracting	 the	 new	 score	 value	 (𝑦E^)	 from	 the	
reference	score	value	(𝑦E)	and	squaring	this	difference.	Squaring	the	difference	ensures	
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that	 any	 negative	 values	 are	 converted	 to	 positive	 to	 prevent	 the	 possibility	 that	
positive	and	negative	errors	will	cancel	each	other	out.	The	mean	is	taken	of	all	 the	
squared	errors	and	the	square-root	(of	the	mean)	is	taken.	When	the	same	reference	is	






5.3 Linear and non-linear modelling 
	








Chapter	 10),	 a	 multinomial	 logistic	 regression	 model	 is	 used.	 This	 compares	 a	
reference	category	(for	example	the	poor-response	class)	with	each	of	the	other	classes	
























is	 to	minimise	 the	 number	 of	 variables	 in	 a	 regression	model,	 and	 not	 choose	 any	
variables	that	may	have	a	collinear	relationship.	The	difficulty	that	arises	here	is	that	



























collinearity	 and	 values	 greater	 than	 5	 are	 highly	 correlated.	 There	 is	 no	 formal	











deleted	without	 significantly	altering	 the	model	 fit.	 If	 a	variable	which	 satisfies	 this	
criterion	is	identified,	it	is	removed	from	the	model	and	the	process	is	repeated	with	
the	remaining	variables,	until	no	further	variables	can	be	deleted	without	significantly	
affecting	 the	 model	 fit.	 Forwards	 stepwise	 regression	 takes	 the	 same	 concept	 as	
backwards	 stepwise	 regression,	 but	 instead	 starts	 with	 no	 variables,	 and	 then	
sequentially	adds	variables	that	significantly	improve	model	fit.	Different	criteria	can	









model.	 However,	 it	 can	 be	 very	 useful	 if	 there	 is	 limited	 information	 to	 help	 with	
selecting	a	limited	set	of	variables	from	an	extensive	list	of	a	priori	specified	variables.	
























GAMs	 are	 a	 useful	 method	 of	 modelling	 non-linear	 relationships	 and	 offer	 a	 less	



















































5.4 Bayesian statistics 
	 	















The	 theorem	 has	 been	 attributed	 to	 the	 Reverend	 Thomas	 Bayes	 (1701	 –	 1761),	
although	his	notes	were	actually	published	posthumously	by	a	 fellow	preacher	and	





𝑃 𝐻 𝐸 = 	





Where	 P(H|E)	 is	 the	 probability	 of	 the	 (prior)	 hypothesis	 (H)	 being	 true	 given	 the	
evidence	(E).	
	






Prior	 to	 the	hypothetical	rheumatology	clinic	commencing,	we	wish	to	calculate	 the	
probability	that	the	first	patient	to	be	seen	will	have	RA.	This	is	the	‘prior	hypothesis’.	
A	list	of	patients	due	to	attend	the	clinic	provides	very	little	information	other	than	the	
patient	 name	 and	 age.	 In	 this	 scenario,	 with	 limited	 information,	 the	 estimated	
probability	 that	 the	 person	 has	 RA	 is	 essentially	 a	 random	 guess.	 However,	 other	
sources	of	information	can	be	used	to	influence	the	probability	of	the	prior	hypothesis	
before	reviewing	the	patient.	An	understanding	that	RA	is	uncommon	in	the	general	
population	 (~1%	of	 the	UK	population	 (33)),	may	 shift	 the	probability	 of	 the	prior	
hypothesis	to	be	less	likely.	However,	incorporating	the	evidence	that	the	clinic	is	in	a	
rheumatology	department,	and	RA	is	the	most	common	inflammatory	arthritis	seen	by	








manner);	 more	 information	 is	 obtained	 allowing	 the	 prior	 to	 be	 updated	 until	 the	
patient’s	final	diagnosis	can	be	concluded	with	a	high	degree	of	confidence.	
	













cancer	 is	0.99	(the	prior	hypothesis).	However,	 the	age	of	 the	patient	 is	essential	 to	
inform	the	prior	hypothesis	if	for	example,	the	cancer	detected	by	the	blood	test	only	
occurs	in	1	in	100	individuals	under	the	age	of	40	(a	probability	of	0.01).	Using	Bayes	





















which	model	 to	use	 following	stepwise	regression	on	multiple	 imputed	datasets.	As	
described	earlier	(Chapter	5;	5.1.4.5.1),	multiple	imputation	creates	multiple	datasets,	
all	 with	 slightly	 different	 values.	 In	 Chapter	 9,	 because	 five	 baseline	 and	 five	
longitudinal	datasets	are	imputed	separately	and	subsequently	combined,	there	are	a	
total	 of	 25	 imputed	 datasets.	 This	 is	 essential	 to	 quantify	 the	 uncertainty	 in	 the	
estimates	that	are	generated	 from	imputed	data.	However,	having	multiple	datasets	
creates	a	potential	problem	when	using	stepwise	regression.	This	is	because	the	slight	
differences	 in	 values	 across	 the	 datasets	 influences	 the	 variables	 that	 are	 selected	
through	the	process	of	stepwise	regression	for	the	final	model,	meaning	that	a	different	
set	of	variables	could	be	selected	for	each	imputed	dataset.	This	could	be	challenging	










down	 into	 the	constituent	variables.	This	 is	because	 if	 the	post-stepwise	 regression	





Posterior	 probabilities	 use	 the	 ability	 of	 Bayesian	 statistics	 to	 update	 or	 test	 a	
hypothesis,	based	on	empirical	data.	Posterior	probabilities	are	used	in	Chapter	10	as	
a	method	 for	examining	 the	 reliability	of	 a	model	 fit	 to	 the	data.	Broadly,	posterior	
probabilities	involve	predicting	the	probability	of	an	event	occurring	given	the	data	or	
evidence	used	to	generate	the	prediction.	In	the	case	of	the	analysis	in	Chapter	10,	the	











of	 the	 model	 given	 the	 data	 can	 be	 checked	 using	 Bayesian	 model	 checking	 and	
posterior	probabilities.	In	this	case,	a	new	dataset	is	generated	using	random	draws	
from	the	distribution	of	the	BSRBR-RA	dataset	used	in	the	analysis.	The	 latent	class	










for	 latent	 class	 analysis.	 BIC	 was	 first	 proposed	 by	 Schwarz	 in	 1978	 (208)	 and	 is	
described	by	the	following	equation:	
	










also	 not	 capable	 of	 managing	 complex	 collections	 of	 models	 or	 high	 dimensional	
statistics	(such	as	stepwise	variable	selection).		
	















a	 bivariate	 normal	 distribution).	 At	 an	 individual	 participant	 level,	 with	 repeated	
measures	over	time,	measurements	would	also	have	a	degree	of	variation.	Therefore,	
there	is	both	between-subject	variation,	as	well	as	within-subject	variation.	There	may	




used	 for	 continuous	 variables	 (209).	 LCMM	 extends	 the	 linear	 mixed	 model	 to	
incorporate	 categorical,	 binary,	 ordinal	 and	 continuous	 but	 asymmetric	 data.	 In	
addition,	 LCMM	 can	 manage	 otherwise	 non-observed	 heterogeneity	 within	 a	
population,	 such	 as	 responders/non-responders	 (essential	 in	 modelling	 multiple	
trajectories	of	response).	LCMM	is	also	able	to	operate	where	longitudinal	processes	







the	duration	of	 the	dataset	and	 ‘joins	the	dots’	of	each	of	 the	sequential	DAS28-ESR	
scores.	 This	 creates	 a	 trajectory	 for	 one	 patient.	 The	 process	 is	 repeated	 for	 each	
patient	record	to	generate	(in	the	case	of	the	BSRBR-RA)	thousands	of	trajectories.	The	




























A	different	version	of	 the	BSRBR-RA	dataset	was	used	 for	 the	analysis	described	 in	
Chapter	 8.	 This	 is	 because	 all	 biologic	 class	 drugs	 (excluding	 Ro-Actemra™)	 were	
included	in	the	analysis	undertaken	in	Chapter	8,	whereas	only	anti-TNF	class	drugs	
were	included	in	the	analyses	undertaken	in	Chapters	9	and	10.	As	there	was	very	little	



















• Only	 patients	 taking	 Enbrel™	 (etanercept),	 Humira™	 (adalimumab),	 Cimzia™	
(certolizumab	pegol)	and	Remicade™	(infliximab)	were	included.	
• Individuals	who	were	not	bio-naïve	at	baseline	were	removed	from	the	dataset.	
• Individuals	 enrolled	 after	 September	 2013	 were	 removed	 from	 the	 dataset.	
Because	this	analysis	focusses	on	data	collected	over	the	first	three	years	of	six-





























(Table	 8).	 The	 greatest	 amount	 of	 missing	 data	 occurs	 in	 the	 DAS28-ESR	 scores	
collected	in	the	longitudinal	dataset	(24.6%).	Because	the	DAS28-ESR	is	generated	by	
a	 calculation	 of	 its	 constituent	 parts	 (the	 tender	 and	 swollen	 joint	 count,	 visual	
analogue	score	and	ESR),	missing	data	in	any	of	these	variables	make	the	calculation	of	
the	 DAS28-ESR	 impossible,	 so	 missingness	 from	 each	 of	 the	 components	 is	
compounded	when	looking	at	the	DAS28-ESR	score.		
	






































































between	 missing	 and	 available	 data	 is	 graphically.	 There	 are	 numerous	 ways	 of	
graphically	representing	missing	data	relationships,	but	two	methods	were	primarily	






Hierarchical	 clustering	 (211)	 (Figure	 8)	 is	 a	 useful	 way	 of	 identifying	 associations	
between	missing	data	in	a	dataset.	By	clustering	missing	data	together,	it	is	possible	to	

















There	 is	 overlap	 with	missingness	 for	 the	 DAS28-ESR	 and	 its	 components.	 This	 is	











that	 is	 of	 concern	 in	 the	 baseline	dataset.	However,	 these	 associations	 are	 likely	 to	
explain	 the	 reason	 that	 the	 null	 hypothesis	 of	 Little’s	 test	 for	 MCAR	 was	 rejected.	
Overall,	there	do	not	appear	to	be	unexpected	associations	between	missing	data	that	
may	 influence	 the	 analysis	 of	 predictors	 of	 sustained	 remission.	 Exploration	 of	 the	
missing	data	in	the	longitudinal	database	was	also	undertaken.	Little’s	test	of	MCAR	
rejected	the	null	hypothesis	of	MCAR.	However,	similar	missing	data	relationships	to	


























from	 the	 analysis	 as	 these	 individuals	 have	 achieved	 part	 of	 the	 outcome	
(remission/LDA)	 before	 starting	 anti-TNF.	 However,	 manually	 removing	 these	
individuals	from	the	analysis	would	generate	a	new	challenge	in	deciding	which	data	
to	remove.	This	is	because	by	removing	these	known	data	from	the	dataset,	artificial	






cohorts	 used	 in	 the	 sustained	 remission	 and	 sustained	LDA	 analysis	 different,	with	
different	 imputation	 parameters.	 Removing	 individuals	 who	 are	 in	 LDA	 or	 less	 at	












Following	 imputation	of	 the	data	 in	the	BSRBR-RA	(used	 in	Chapters	9	and	10),	 the	
distribution	 of	 the	 values	 of	 the	 imputed	 variables	 was	 compared	 against	 the	





































As	mentioned	 previously	 (Chapter	 5;	 5.1.5.2),	 imputing	 data	 that	 are	 derived	 from	
components	 that	 are	 also	 imputed	 could	 lead	 to	 implausible	 relationships	 (i.e.	 an	
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imputed	 DAS28-ESR	 score	 may	 not	 be	 the	 same	 as	 the	 score	 calculated	 by	 its	
component	parts	 for	 that	 record).	Therefore,	 a	 secondary	DAS28-ESR	score	column	
(DAS28-2)	 was	 created	 (post-imputation)	 and	 DAS28-ESR	 scores	 were	 calculated	
based	 on	 the	 (original	 and	 imputed)	 component	 parts	 of	 the	 DAS28-ESR.	 The	
distribution	 of	 these	 DAS28-2	 data	 were	 then	 compared	 with	 distribution	 of	 the	
complete	 and	 imputed	 DAS28-ESR	 values	 and	 were	 not	 found	 to	 be	 significantly	
different.	 Therefore,	 to	 minimise	 any	 impossible	 relationships	 between	 the	




data	 for	 the	 tender	 and	 swollen	 joint	 counts,	 the	 DAS28-ESR	 data	 was	 a	 good	 fit.	
Because	 identification	 of	 individuals	 in	 sustained	 remission	 and	 LDA	 will	 use	 the	
DAS28-ESR	values	rather	than	the	components	of	 the	score,	 the	 imputed	values	are	
acceptable	to	proceed	with	analysis.			
	




remission	 or	 LDA	 for	 two	 consecutive	 follow-ups	 to	 be	 identified.	 This	 presents	 a	
challenge	as	the	longitudinal	component	of	the	BSRBR-RA	is	presented	in	‘long-format’	
(i.e.	sequential	follow-up	visits	are	added	as	additional	rows	in	the	dataset,	rather	than	
additional	columns).	To	 identify	an	 individual	who	has	two	sequential	 follow-ups	at	
any	point	within	the	first	six	follow-up	visits,	a	looping	function	could	be	created	that	
‘reads’	down	 the	dataset	 and	 identifies	any	 two	 rows	 that	are	 in	 remission	or	LDA.		

































is	 identified.	 Finally,	 to	 avoid	 patients	 with	 more	 than	 one	 episode	 of	 sustained	












6.4 Chapter discussion 
	
As	was	expected,	missing	data	were	 identified	 in	 the	BSRBR-RA	dataset.	These	data	
were	not	MCAR.	However,	visual	examination	of	the	dataset	and	appraisal	of	the	study	
methods	 has	 not	 demonstrated	 any	 significant	 concerns	 that	 the	 pattern	 of	




The	 imputed	 DAS28-ESR	 data	 had	 a	 good	 approximation	 with	 the	 original	 data	
however,	 and	 as	 the	 DAS28-ESR	 data	 were	 used	 to	 identify	 patients	 in	 sustained	
remission/LDA,	use	of	the	imputed	dataset	was	acceptable.		
	
Identification	 of	 sustained	 remission	 and	 LDA	 was	 possible	 using	 binary	 vector	
multiplication,	 which	 will	 allow	 analysis	 of	 these	 outcomes	 to	 be	 subsequently	
examined	(Chapters	9	and	10).	
	











































7.2 Patients and methods 
	
The	 systematic	 review	 protocol	 was	 registered	 prospectively	 with	 the	 PROSPERO	
database	 (http://www.crd.york.ac.uk/PROSPERO/,	 reference	 CRD42015015983).	
PRISMA-P	 (213)	 and	 PRISMA	 (214)	 recommendations	 were	 followed	 in	 the	
development,	implementation	and	reporting	of	the	review.	
	












4. Report	 on	 at	 least	 one	 measure	 of	 RA	 disease	 activity	 using	 DAS	 (146),	 DAS28	





7.4 Exclusion criteria 
	
Studies	where	it	was	not	possible	to	isolate	the	required	data	on	patients	in	sustained	











































































































































































7.6 Assessment of studies for inclusion into the review 
	
All	 search	 results	were	dual	 screened	with	dual	data	extraction	and	quality	 scoring	
using	 a	 custom	 Access™	 database.	 The	 quality	 of	 studies	 was	 assessed	 using	 the	
Newcastle-Ottawa	Scale	(217).		A	narrative	review	of	studies	with	relevant	quantitative	







Because	 the	 factors	 incorporated	 in	 calculating	 adjusted	odds	 ratios	 (OR)	were	not	
consistent	 between	 studies,	 unadjusted	OR	were	 used	 in	meta-analysis	where	 data	
were	available	from	at	least	three	studies.	A	random	effects	model	was	used	to	allow	








excluded	 and	 218	 full	 text	 papers,	 including	 50	 randomised	 controlled	 trials,	were	
assessed.	Six	papers	met	the	inclusion	criteria	and	were	included	in	the	review	(220-
225).	One	of	these	papers	(224)	had	included	one	patient	aged	less	than	18	years	old	
in	 one	 subgroup	 (personal	 correspondence),	 however,	 the	 mean	 age	 of	 all	 the	
subgroups	and	the	overall	cohort	was	in	line	with	the	other	included	papers,	and	it	was	
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The	 definitions	 of	 sustained	 remission	 varied	 across	 the	 included	 studies.	 The	
minimum	length	of	time	that	different	studies	defined	sustained	remission	as,	varied	
from	at	least	six	months,	to	nine	months,	or	‘two	consecutive	visits’	(verified	to	be	at	
least	 six	 months	 (226));	 and	 a	 range	 of	 outcome	 measures	 (DAS28,	 CDAI,	 SDAI,	


























The	 studies	 identified	 in	 this	 systematic	 review	 include	 a	 range	 of	 anti-TNF	
medications.	 Some	studies	 (220,222,223,225)	 specifically	 reported	which	anti-TNFs	
were	studied,	whereas	the	studies	by	Furst	et	al.	(221)	and	Balogh	et	al.	(224)	did	not.	
Very	 little	 data	 was	 available	 for	 patients	 using	 the	 newer	 anti-TNF	 medications	
(certolizumab	pegol	and	golimumab),	and	no	data	were	available	for	biosimilar	anti-




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































al.	 (223),	 and	was	 not	 reported	 by	 the	 remaining	 studies	 (222,224).	Meta-analysis	



















































criteria	 (220)	 and	DAS28	 criteria	 (224).	However,	 no	 association	was	 identified	 by	
Tanaka	et	al.(223).	A	higher	swollen	joint	count	was	not	identified	as	being	associated	














One	 study	 identified	 that	 increased	 disease	 duration	 (stratified	 into	 five-yearly	























Prednisolone	 use	was	 negatively	 associated	with	 sustained	 CDAI	 but	 not	 sustained	
DAS28	remission	 in	one	study	 (221).	However,	no	association	was	 identified	 in	 the	
study	by	Einarsson	et	al.	(225).	Prednisolone	use	was	restricted	to	a	stable	dose	of	less	
than	5mg	 in	 one	 study	 (222)	 and	patients	 taking	 concomitant	 corticosteroids	were	








anti-TNF	 and	 found	 that	 etanercept	was	 associated	with	 an	 increased	 likelihood	 of	
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achieving	 sustained	 remission	 within	 the	 first	 twelve	 months	 on	 treatment	 when	
compared	with	infliximab.	
	





outcome.	 From	 over	 4000	 possible	 manuscripts	 identified	 in	 the	 search,	 only	 six	
studies	 were	 identified	 which	 met	 the	 inclusion	 criteria,	 all	 of	 which	 were	










A	 number	 of	 clinical	 factors	 including	 increased	 disease	 duration,	 higher	 baseline	
disease	 activity	 score,	 increased	baseline	 tender	 joint	 count,	 and	 a	 greater	 baseline	
functional	impairment	are	associated	with	a	reduced	likelihood	of	achieving	sustained	
remission	 in	 individual	 studies.	 Demographic	 factors	 that	 appear	 to	 be	 negatively	
associated	with	sustained	remission	include	female	gender	and	increasing	age.	Only	
one	clinical	 factor	 (methotrexate	 co-prescription)	was	associated	with	an	 increased	
likelihood	of	achieving	sustained	remission	in	more	than	one	study.	Supporting	these	
findings,	Katchamart	et	al.	also	identified	these	factors	as	predictors	of	point	remission	
in	 a	 systematic	 review	 (212).	 Interestingly,	 the	 rates	of	 sustained	DAS28	 remission	
identified	 in	 this	 review	 (7.9	 -	 38.1%)	 compare	 favourably	with	 the	 range	 of	 point	
DAS28	remission	rates	(5	-	40%)	identified	by	Katchamart	et.	al.	However,	the	studies	
identified	by	Katchamart	et	al.	included	both	biologic	and	synthetic	DMARD	treated	RA	




This	 review	 of	 the	 literature	 identified	 that	 female	 gender	 appears	 to	 be	 strongly	
associated	with	a	 reduced	 likelihood	of	achieving	sustained	remission	 in	 two	of	 the	
included	studies.	However,	female	gender	has	been	associated	with	a	higher	baseline	
















achieving	 sustained	 remission.	 However,	 it	 remains	 uncertain	 whether	 worse	
functional	impairment	is	a	true	predictor	of	response,	or	acting	as	a	proxy	marker	of	
recalcitrant	higher	disease	activity,	 irreversible	 joint	damage,	pain	or	 fatigue,	which	
may	not	be	responsive	to	anti-TNF.	
	
The	only	 intervention	that	was	associated	with	an	 increased	 likelihood	of	achieving	








Einarsson	 et	 al.	 (225)	 both	 describe	 collection	 of	 comorbidity	 data,	 however	 no	
analysis	 was	 reported.	 None	 of	 the	 other	 studies	 included	 any	 reporting	 on	
comorbidity	 data.	 The	 association	between	RA	 and	 increased	 cardiovascular	 risk	 is	




Interaction	 between	 predictors	 and	 outcomes	 is	 challenging	when	 using	 composite	




of	 this	 is	 the	 association	 between	 higher	 baseline	 tender	 joint	 count	 and	 reduced	
likelihood	of	achieving	sustained	remission.	It	is	unknown	if	having	more	tender	joints	
prior	to	starting	anti-TNF	is	a	negative	predictor	of	achieving	sustained	remission,	or	
whether	 there	 is	 interaction	 with	 the	 composite	 outcome	 measure,	 within	 which	
tender	 joint	 count	 comprises	 a	 component.	 This	 review	 also	 identified	 that	 higher	
	 165	
baseline	 disease	 activity	was	 negatively	 associated	with	 the	 likelihood	 of	 achieving	
sustained	 remission,	 although	 it	 is	 possible	 that	 this	 association	 is	 on	 the	 causal	
pathway	in	the	relationship	between	tender	joint	count	and	sustained	remission.	As	
previously	discussed	(Chapter	2),	it	is	possible	that	composite	disease	activity	scores	




















environmental	 aids	 or	 barriers	 and	 personal	 factors	 all	 interact	 in	 an	 individual’s	
perception	 of	 health.	 All	 the	 composite	 outcome	measures	 included	 in	 this	 review	
contain	measures	that	indirectly	measure	these	non-disease	dimensions	(such	as	the	







of	 active	 RA,	 it	may	 be	 that	 a	 patient’s	 pain	 and	 fatigue	 is	 driven	 by	 other	 factors,	
unrelated	to	their	RA.	In	these	cases,	classifying	the	patient	as	a	‘non-responder’	to	anti-
TNF	 is	 inappropriate;	 targeting	 external	 factors	 (such	 as	 low	 mood,	 altered	 pain	
perception	 or	 challenging	 life	 situations)	 may	 be	 more	 efficacious	 in	 achieving	
‘remission’	than	stopping	or	switching	drug.	As	previously	described,	the	non-specific	
nature	of	the	global	health	measure	allows	for	many	aspects	of	health	and	quality	of	




inflammatory	component.	A	 recent	Cochrane	 review	has	 shown	an	 improvement	 in	
fatigue	 in	 response	 to	 anti-TNF	and	other	biologic	 therapy,	 although	modest	 (232).	





Composite	outcome	measures	are	essential	 in	understanding	 the	global	 impact	of	 a	
complex	multisystem	disease	such	as	RA.	However,	with	increasingly	aggressive	treat-
to-target	 treatment	 regimes,	 it	 may	 be	 more	 appropriate	 to	 consider	 which	
components	of	 the	composite	measure	are	driving	a	patient’s	 ‘failure	to	respond’	 to	
anti-TNF	rather	than	solely	relying	on	the	final	composite	score.		
	
7.10  Conclusions 
	









The	associations	 identified	 in	 this	 chapter	will	be	used	as	 the	 foundations	 for	 the	a	
priori	 variables	 specified	 in	 the	 analysis	 of	 sustained	 remission	 in	 the	 BSRBR-RA	
(Chapter	 9).	 Additionally,	 consideration	 will	 be	 given	 to	 addressing	 the	 issue	 of	
multiple	collinearity	between	the	predictors	of	response,	used	in	the	final	model.		
	
It	 is	 evident	 from	 reviewing	 the	 existing	 evidence	 that	 the	 predictors	 of	 sustained	
remission	vary	considerably	depending	on	the	outcome	measure	used.	As	previously	
discussed	 (Chapter	2;	2.1.2)	 there	 is	evidence	 that	 suggests	 the	 two	versions	of	 the	
DAS28	may	 not	 in	 fact	 be	 interchangeable,	 although	 they	 are	 used	 side-by-side	 in	
clinical	practice	(155-157).	The	BSRBR-RA	does	not	specify	which	version	of	the	DAS28	
should	be	used,	and	as	such,	the	composite	DAS28	score	recorded	contains	a	mixture	










• Demographic	 and	 clinical	 features	 can	 help	 to	 predict	 sustained	 remission	with	
anti-TNF.	
	
• Female	 gender	 is	 associated	 with	 a	 reduced	 likelihood	 of	 achieving	 sustained	
remission.	
	



















rate	 (ESR)	 (147,233).	 The	 development	 of	 the	 DAS28-CRP	 followed	 assessment	 of	
paired	 samples	 obtained	 from	 a	 relatively	 small	 cohort	 of	 334	 patients	 with	
subsequent	wide	adoption	in	clinical	practice	and	trial	settings	(215).	The	DAS28-CRP	





compared	 to	DAS28-ESR	 scores,	 particularly	 at	 lower	 levels	 of	 disease	 activity	 that	
form	 the	 focus	 of	 treat-to-target	management	 (155-157,234,235).	 This	 disparity	 in	




Such	 disparity	 is	 of	 direct	 relevance	 when	 attempting	 to	 identify	 predictors	 of	















2. To	 investigate	 if	 common	demographic	 factors	 influence	 the	 level	 of	 inter-score	
agreement.		
	
3. To	use	paired	DAS28-ESR	and	DAS28-CRP	data	on	 the	BSRBR	to	 investigate	 if	a	
modified	version	of	the	DAS28-CRP	could	improve	inter-score	agreement.			
	
8.3 Null hypothesis 
	








treated	with	 any	 biologic	 therapy	with	 concurrent	measures	 of	 ESR	 and	 CRP	were	
identified,	 enabling	paired	 calculation	of	DAS28-ESR	and	DAS28-CRP	using	 existing	



















8.5 Development of  the modified DAS28-CRP 
	
A	 nonlinear	 generalized	 additive	model	 with	monotonically	 constrained	 increasing	










Resultant	 predicted	 ESR	 values	 were	 used	 in	 the	 existing	 DAS28-ESR	 formula	 to	
calculate	 the	 estimated	 disease	 activity,	 or	 modified	 DAS28-CRP	 (mDAS28-CRP).	
Kappa	values	and	 root	mean	squared	error	 (RMSE;	Chapter	4)	 calculated	 the	mean	
error	of	DAS28-CRP	and	mDAS28-CRP	(200).	The	differences	 in	errors	between	the	































Comparison	 of	 missing	 and	 complete	 datasets	 respective	 to	 age,	 gender,	 disease	
duration	and	BMI	did	not	reveal	any	significant	differences	between	the	two	groups,	
suggesting	 MAR	 was	 a	 reasonable	 assumption,	 and	 LOCF	 imputation	 using	 age	 at	
enrolment	to	the	BSRBR-RA	was	used.	
	
	 Complete	data	set	 Missing	data	set	 P	value	
Number	of	paired	readings	 25472	 5602	 NA	
Mean	Baseline	Age	(yrs,	SD)	 55.5	(12.1)	 55.7	(12.1)	 0.5	
Gender	(%	Female)	 76.4	 75.6	 0.3	
Mean	 Baseline	 Disease	 Duration	
(yrs,	SD)	
12.8	(9.5)	 12.8	(9.4)	 0.7	




















Overall	 4.44	 4.13	 0.30	 0.30	to	0.31	 31074	
Male	 4.17	 4.02	 0.15	 0.13	to	0.16	 7380	
Female	 4.52	 4.17	 0.35	 0.35	to	0.36	 23694	
Ag
e	
<50	 4.27	 4.09	 0.17	 0.16	to	0.19	 7786	
>50	 4.50	 4.15	 0.35	 0.34	to	0.35	 23288	
Underweight	(<18.5)	 4.51	 4.19	 0.32	 0.29	to	0.35	 1054	
Normal	(18.5	-	<	25)	 4.34	 4.04	 0.30	 0.29	to	0.31	 12348	
Overweight	(25	-	<	30)	 4.43	 4.15	 0.29	 0.28	to	0.30	 9988	


















































































































Overall	 4.44	 4.61	 -0.17	 -0.18	to	-0.17	 31074	
Male	 4.17	 4.49	 -0.34	 -0.34	to	-0.31	 7380	
Female	 4.52	 4.65	 -0.12	 -0.13	to	-0.12	 23694	
Ag
e	 <50	 4.27	 4.57	 -0.30	 -0.32	to	-0.29	 7786	
>50	 4.50	 4.62	 -0.13	 -0.13	to	-0.12	 23288	
Underweight	(<18.5)	 4.51	 4.66	 -0.16	 -0.18	to	-0.12	 1054	
Normal	(18.5	-	<	25)	 4.34	 4.51	 -0.18	 -0.19	to	-0.17	 12348	
Overweight	(25	-	<	30)	 4.43	 4.62	 -0.19	 -0.20	to	-0.18	 9988	









































































The	DMARD	 control	 cohort	 from	 the	BSRBR-RA	was	 used	 as	 an	 internal	 validation	
cohort.	Patients	 in	 the	DMARD	control	cohort	were	slightly	older	 than	 the	biologics	
cohort	(58.2	vs	57.3	years	respectively),	and	there	was	a	lower	proportion	of	women	
compared	 with	 the	 biologics	 cohort	 (73%	 vs	 76%).	 The	 overall	 number	 of	 paired	







































Remission	(<2.6)	 57.7	 80.0	 21	 26	 15	
LDA	(2.6	-	≤3.2)	 51.7	 52.9	 31	 29	 17	
MDA	(3.2	-	≤5.1)	 69.3	 81.4	 229	 306	 220	












8.7 Chapter discussion 
	
This	 analysis	 supports	 existing	 evidence	 suggesting	 DAS28-ESR	 and	 DAS28-CRP	








interchangeability	 cannot	 have	 been	 said	 to	 have	 been	 demonstrated	 and	 concern	








for	 older	 patients	 and	 women	 (demographics	 representing	 the	 majority	 of	 the	 RA	






superior	 agreement	with	 the	DAS28-ESR	compared	 to	 the	original	DAS28-CRP.	The	
improvement	in	agreement	of	disease	activity	stratification	at	lower	disease	activity	
thresholds	was	achieved	at	 the	expense	of	a	minor	reduction	 in	agreement	at	HDA.	
However,	 the	 effect	 of	 this	 in	 clinical	 practice	 would	 be	 to	 encourage	 more	 active	
treatment	 for	 patients	 with	 higher	 disease	 activity,	 in	 line	 with	 current	 treatment	
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paradigms.	Younger	and	male	patients	have	the	 lowest	 inter-score	agreement	using	



















of	 the	mDAS28-CRP	in	 larger	external	cohorts	 is	necessary	before	the	mDAS28-CRP	
could	be	widely	adopted.	Other	research	groups	from	Canada	(CATCH	Registry)	and	
the	Netherlands	(Dutch	RA	Quality	Register)	have	expressed	interest	in	participating	




relevant	 to	 this	 thesis	 is	 that	 the	 DAS28-ESR	 and	 DAS28-CRP	 should	 not	 be	 used	







undertaken	 in	 this	 thesis	 for	 two	 reasons.	As	mentioned	previously,	 the	 score	does	
need	further	validation	 in	cohorts	outside	of	 the	BSRBR-RA	to	ensure	the	 improved	
agreement	between	the	DAS28-ESR	and	mDAS28-CRP	is	maintained.	Secondarily,	use	
of	the	mDAS28-CRP	would	not	‘solve’	the	issue	of	missing	data	in	the	BSRBR-RA	to	be	
used	 in	 subsequent	 analyses.	 As	 such	 multiple	 imputation	 will	 still	 be	 required.	
Because	the	mDAS28-CRP	has	a	slightly	different	relationship	between	its	component	
parts	 and	 final	 score	 compared	 to	 the	 DAS28-ESR,	 this	would	 likely	 impact	 on	 the	









• Inter-score	 discrepancies	 have	 a	 significant	 impact	 on	 disease	 activity	
stratification.	
	























































9.3 Null hypothesis 
	
The	null	hypothesis	of	this	analysis	is	that	there	are	no	associations	between	baseline	
clinical	 and	 demographic	 factors	 and	 the	 attainment	 of	 sustained	 remission	 or	
sustained	LDA	according	to	the	DAS28-ESR.	
	
















adverse	 events	 or	 non-response).	 This	 may	 include	 switching	 within	 class	 (i.e.	




such	 as	 anti-TNF,	 act	 by	 modifying	 the	 cellular	 signalling	 pathways	 which	 in	 turn	


















agent.	 In	 addition,	 binary	 vector	 multiplication	 (Chapter	 6;	 6.3.1)	 will	 be	 used	 to	










the	 first	 three	 years	 that	 a	 patient	 is	 enrolled	 on	 the	 database.	 Thereafter,	 data	
collection	 reduces	 to	 an	 annual	 frequency.	 Therefore,	 a	 pragmatic	 approach	 to	 the	
operationalisation	 of	 the	 definition	 of	 sustained	 remission/LDA	was	 applied	 to	 the	
BSRBR-RA	dataset.	To	qualify	as	sustained	remission	or	sustained	LDA,	a	patient	will	
need	to	have	a	DAS28-ESR	score	of	less	than	2.6	or	3.2	respectively,	on	two	sequential	










used	 to	enable	 identification	of	 sequential	 follow-up	visits	and	periods	of	 sustained	
remission/LDA.	 Whilst	 there	 will	 be	 variation	 in	 when	 follow-ups	 occur	 between	
individuals,	the	alternative	would	be	to	artificially	apply	date/time	thresholds	within	


















Whilst	 accepting	 there	will	 be	 variability	 in	 the	 time	 between	 follow-up	 visits	 is	 a	
limitation,	the	alternative	method	to	correct	this	variability	is	likely	to	misrepresent	

















As	discussed	 in	Chapter	7	 (7.9),	one	of	 the	difficulties	when	examining	associations	
with	 sustained	 remission	 and	 LDA	 as	 defined	 by	 a	 composite	 outcome	 such	 as	 the	
DAS28-ESR	is	that	some	of	the	key	variables	that	would	be	of	interest	to	investigate	
(such	 as	 the	 tender	 and	 swollen	 joint	 count)	 are	 also	 variables	 in	 the	 outcome	 of	
interest	(the	DAS28-ESR).	Additionally,	variables	such	as	number	of	swollen	and/or	
tender	joints	are	likely	to	be	strongly	interrelated	at	an	individual	level.	This,	coupled	
with	 the	 multiple	 clinical	 and	 demographic	 predictors	 to	 be	 analysed,	 mean	 that	
collinearity	between	variables	is	likely	to	be	a	significant	issue	in	interpreting	results.	







The	 first	step	uses	existing	evidence	 from	multiple	sources	(i.e.	different	papers)	 to	
establish	prior	hypotheses	(i.e.	which	variables	are	likely	to	be	of	 importance	in	the	
model).	The	second	step	uses	stepwise	regression	and	collinearity	modelling	to	assess	
if	 the	number	of	 variables	 in	 the	model	 can	be	 reduced.	 Confidence	 in	 the	 selected	




may	 be	 attributed	 to	 other	 variables.	 If	 the	 VIF	 is	 reduced	 following	 stepwise	









model	 that	constitutes	the	second	stage	of	a	 two-stage	should	take	 into	account	the	
previous	screening	of	variables	based	on	significance	in	univariable	analyses.	There	is	































































21).	 This	 can	 lead	 to	 false	 identification	 of	 causality	 between	 an	 exposure	 and	 an	
outcome.	If	confounding	is	not	identified,	the	outcome	may	in	fact	be	caused	by	another	
	 191	
unmeasured	 factor	 that	 is	 related	 to	 both	 the	 outcome	 and	 the	 exposure,	 but	 not	
included	in	the	model.	It	is	important	to	note	that	in	an	epidemiological	study	such	as	
the	BSRBR-RA,	it	is	not	possible	to	establish	causality	as	this	requires	a	study	with	a	






































One	 of	 the	most	 complex	 relationships	 to	 establish	 is	 the	 choice	 of	 anti-TNF	 agent.	
Because	the	choice	of	anti-TNF	agent	is	likely	to	be	influenced	by	a	multitude	of	factors,	
it	is	difficult	to	identify	a	true	association	between	choice	of	anti-TNF	and	remission	as	
an	 outcome	 (known	 as	 confounding	 by	 indication;	 Figure	 23).	 However,	 it	 is	 still	
worthwhile	including	drug	choice	in	the	regression	models	as	it	is	useful	to	understand	







in	 the	 full	 logistic	 regression	 models	 used.	 However,	 one	 of	 the	 drawbacks	 of	




























(243).	 The	 publication	 of	 such	 updated	practice,	 and	 the	 natural	 pause	 in	 registers	
recruitment	windows,	makes	the	year	2010	an	appropriate	time	to	split	the	cohort,	and	
allows	 further	 investigation	 into	whether	demographics	or	outcomes	of	patients	on	
anti-TNF	medications	has	changed	over	time.	Although	recruitment	paused	from	2007	



























Number	 14436	 13115	 1321	 NA	
Female	(%)	 76.3	 76.3	 75.7	 0.6	
Age	(yrs,	SD)	 56.0	(12.3)	 56.0	(12.2)	 56.3	(12.7)	 0.4	
DAS28-ESR	(SD)	 6.5	(1.0)	 6.6	(1.0)	 6.0	(1.0)	 <0.01	
Swollen	 Joint	 Count	
(SD)	
11.1	(6.2)	 11.4	(6.2)	 8.7	(5.2)	 <0.01	
Tender	 Joint	 Count	
(SD)	
15.5	(7.4)	 15.6	(7.4)	 14.6	(7.5)	 <0.01	
Patient	 Global	 Score	
(SD)	
72.5	(19.8)	 72.5	(19.8)	 72.2	(19.5)	 0.6	
ESR	(SD)	 44.7(28.2)	 46.0	(28.3)	 29.6	(22.8)	 <0.01	
HAQ	(SD)	 2.0	(0.6)	 2.0	(0.6)	 1.6	(0.7)	 <0.01	












Enbrel™,	N	(%)		 4852	(33.6)	 4449	(33.9)	 376	(28.5)	 NA	
Remicade™,	N	(%)	 4222	(29.2)	 4196	(32.0)	 26	(2.0)	 NA	
Cimzia™,		N	(%)	 659	(4.6)	 0.0	 659	(49.9)	 NA	




0.03	Ever	smoke,	N	(%)	 5368	(37.7)	 4922	(37.8)	 446	(36.0)	





























vs.	2010-2013)	 shows	a	 significant	 increase	 in	 the	proportion	of	patients	 achieving	
both	sustained	and	point	remission	(Table	24).	
	
Sustained	LDA	 is	 also	 infrequent,	with	only	3802	patients	 (26.3%)	 identified	 in	 the	
whole	cohort.	Just	over	half	of	those	patients	(2144)	who	had	achieved	sustained	LDA	
had	also	achieved	sustained	remission,	and	1031	(27%)	of	the	sustained	LDA	group	




non-sustained	 remission	 remained	 stable	 over	 the	 two	 subgroups	 examined	 (7.1	 –	
8.0%).	 However,	 the	 proportion	 of	 patients	 who	 have	 never	 achieved	 point	 or	
sustained	remission	 in	 the	sustained	LDA	group	reduced	significantly	 from	4.4%	to	
2.7%,	although	numbers	are	 small	 for	 the	2010-2013	subgroup.	 Stratifying	by	 time	
shows	that	the	proportion	of	patients	achieving	sustained	LDA	increased	significantly,	






Cohort	Dataset	 2001	-	2013	 2001	-	2010	 2010	-	2013	 p-value	











































































































































































































































































































































































































































































































































































































particularly	 with	 DAS28-ESR,	 which	 has	 a	 VIF	 of	 3.31	 (evidence	 of	 multiple	
collinearity).	 	Neither	 the	DAS28-ESR,	S:TJR,	disease	duration,	 tender	 joint	 count	or	






between	 the	 two	 models	 (analysis	 of	 variance;	 ANOVA	 p-value	 0.90;	 Table	 27).	
Compared	with	 the	 full	 regression	model,	 none	of	 the	 identified	associations	 in	 the	
reduced	regression	model	change	in	direction,	and	the	tender	joint	count	is	identified	
as	having	a	significant	association	with	sustained	remission	in	the	reduced	regression	
model.	 In	 further	 support	 of	 the	 model	 simplification,	 all	 the	 VIFs	 are	 reduced	
compared	with	the	original	full	model.	
	
As	 identified	 in	 the	 systematic	 review,	 female	 gender	 and	 poor	 baseline	 functional	
status	(HAQ),	are	strongly	associated	with	a	reduced	likelihood	of	achieving	sustained	




count	 and	 ex-smoker	 status	 (but	 not	 never	 smoker	 status)	 are	 associated	 with	 an	
improved	chance	of	achieving	sustained	remission	in	both	models.	An	increased	PGA	
is	also	noted	to	be	significantly	associated	with	an	increased	likelihood	of	achieving	










Examining	 the	 2001-2010	 subgroup	 within	 the	 BSRBR,	 many	 of	 the	 significant	
predictors	of	sustained	remission	remain	the	same	as	the	overall	2001	-	2013	cohort	




the	 whole	 cohort.	 An	 increasing	 baseline	 DAS28-ESR	 appears	 to	 be	 negatively	
associated	with	the	attainment	of	sustained	remission	in	both	regression	models	for	
the	 2001-2010	 subgroup	 (Table	 26	 and	 Table	 27),	which	was	 not	 identified	 in	 the	
regression	 model	 for	 the	 overall	 cohort.	 Stopping,	 or	 never	 smoking	 is	 positively	
associated	 with	 the	 likelihood	 of	 achieving	 sustained	 remission	 in	 the	 reduced	



























the	 2001-2010	 subgroup,	 higher	 baseline	 HAQ	 is	 negatively	 associated	 with	 the	
likelihood	 of	 achieving	 sustained	 remission.	 Likewise,	 higher	 ESR	 levels	 prior	 to	
commencing	anti-TNF	are	also	negatively	associated	with	the	likelihood	of	achieving	





not	 identified	 in	 either	 the	 whole	 cohort	 analysis	 or	 in	 the	 2001-2010	 subgroup	









models	 for	 the	 2001	 –	 2010	 subgroup	 and	 full	 cohort	 regression	 models.	 This	 is	
unsurprising	 given	 the	 2001	 –	 2010	 cohort	 contains	 13115	 of	 the	 14436	 patients	













Gender	 -	 -	 Nil	
HAQ	 -	 -	 -	
DAS28-ESR	 Nil	 -	 Nil	
BMI	 -	 -	 Nil	
Swollen:tender	joint	count	ratio	 Nil	 Nil	 Nil	
Disease	duration	 Nil	 Nil	 Nil	
Tender	joint	count	 Nil	 Nil	 Nil	
Swollen	joint	count	 +	 +	 Nil	
PGA	 +	 +	 Nil	
ESR	 -	 -	 Nil	
Ex-smokers	(vs.	smokers)	 +	 +	 	
Never-smokers	(vs.	smokers)	 Nil	 +	 Nil	
Age	at	starting	biologic	 -	 -	 Nil	
Remicade™	(vs	Enbrel™)	 -	 -	 Nil	
Cimzia™	(vs	Enbrel™)	 Nil	 Nil	 Nil	
Humira™	(vs	Enbrel™)	 +	 +	 Nil	







As	 outlined	 in	 Table	 24,	 just	 over	 half	 (56%)	 of	 those	 individuals	 who	 achieved	
sustained	LDA	also	 achieved	 sustained	 remission.	When	examining	 the	2010	 -2013	
subgroup,	 this	 increased	 to	 two	 thirds	 (67%)	 of	 the	 sustained	 LDA	 group,	
demonstrating	a	significant	improvement	in	outcomes	over	time.	Consequently,	many	
of	 the	 predictors	 of	 sustained	 remission	 are	 likely	 to	 be	 identified	 as	 predictors	 of	
sustained	 LDA.	 However,	 approximately	 a	 quarter	 of	 patients	 who	 achieve	 LDA	










are	a	 few	minor	differences	however.	An	 increasing	tender	 joint	count	 is	associated	
with	a	reduced	likelihood	of	achieving	sustained	LDA	(in	both	full	and	reduced	LDA	
regression	 models),	 and	 a	 more	 recent	 year	 of	 starting	 anti-TNF	 is	 significantly	
associated	with	an	increased	likelihood	of	achieving	sustained	LDA	but	not	sustained	
remission.	Cimzia™	use	is	associated	with	a	reduced	likelihood	of	achieving	sustained	
LDA	 compared	 to	 Enbrel™	 in	 both	 the	 full	 and	 reduced	models	 for	 sustained	 LDA,	
something	that	was	not	identified	in	the	analysis	of	sustained	remission.	The	PGA	does	
not	appear	to	be	associated	with	sustained	LDA	where	it	is	associated	with	sustained	
remission	 in	both	 the	 full	 and	 reduced	 regression	models.	The	DAS28-ESR	was	not	
included	 as	 a	 variable	 in	 the	 reduced	 regression	 model	 for	 sustained	 LDA	 (unlike	
sustained	remission).	
	
Although	 all	 the	 remaining	 significant	 associations	 are	 the	 same	 as	 the	 equivalent	





























































































































































































































































































































































































































































































































associated	with	an	 increased	 likelihood	of	 achieving	 sustained	LDA	 in	both	 full	 and	





































sustained	 remission	 (who	 are	 included	 in	 the	 LDA	 cohort).	 When	 considering	 the	
proportion	of	patients	who	achieve	sustained	LDA,	but	not	sustained	remission,	this	
has	 decreased	 from	 44%	 to	 33%	 comparing	 the	 2001	 –	 2010	 and	 2010	 –	 2013	
subgroups	 respectively.	 Furthermore,	 the	 proportion	 of	 patients	 who	 achieve	
sustained	LDA	but	never	achieve	any	episode	of	remission	has	decreased	significantly	
























Gender	 -	 -	 Nil	
HAQ	 -	 -	 -	
DAS28-ESR	 Nil	 Nil	 Nil	
BMI	 -	 -	 -	
Swollen:tender	joint	count	ratio	 Nil	 Nil	 +	
Disease	duration	 Nil	 Nil	 Nil	
Tender	joint	count	 -	 -	 Nil	
Swollen	joint	count	 +	 +	 Nil	
PGA	 Nil	 +	 Nil	
ESR	 -	 -	 -	
Ex-smokers	(vs.	smokers)	 +	 +	 Nil	
Never-smokers	(vs.	smokers)	 Nil	 Nil	 Nil	
Age	at	starting	biologic	 -	 -	 Nil	
Remicade™	(vs	Enbrel™)	 -	 -	 -	
Cimzia™	(vs	Enbrel™)	 -	 NA	 Nil	
Humira™	(vs	Enbrel™)	 +	 +	 Nil	









This	 analysis	 shows	 that	 the	demographics	 and	 clinical	 features	 of	 patients	 treated	
with	anti-TNF	in	the	UK	over	a	12-year	period	have	changed	significantly	(Table	23).	
Subgroup	 analysis	 has	 revealed	 that	 individuals	 are	 being	 treated	 earlier	 in	 their	
disease	 course,	 with	 a	 significant	 reduction	 in	 disease	 duration	 at	 time	 of	













possible	 explanations	 for	 such	 a	 result.	 It	 is	 possible	 that	 older	 patients	 are	 more	





in	 the	 population	 prevalence	 of	 known	 exacerbating,	 and	 possibly	 precipitating,	
features	of	RA	such	as	smoking.	In	support	of	this,	the	prevalence	of	both	current	and	
ex-smokers	has	reduced	significantly	between	the	two	subgroups	analysed.	A	further	









reduced	 significantly	 as	well,	 it	 has	 only	 reduced	by	1	 (from	15.6	 to	14.6).	What	 is	
striking	however,	is	that	although	overall	disease	activity	has	reduced	significantly,	the	
patient	 perception	 of	 the	 overall	 disease	 impact,	 as	 quantified	 by	 the	 PGA,	 has	 not	
reduced	at	all	between	the	two	subgroups,	and	has	remained	almost	identical	over	time	
at	72mm	(Table	23).	This	may	be	because	the	patient	perceived	relationship	between	





patients	 included	 in	 the	 2010	 -	 2013	 subgroup,	 and	 hence	 greater	 motivation	 for	
patients	 to	 express	 the	 impact	 of	 symptoms	 on	 their	 lives,	 rather	 than	 adopting	 a	
‘stoical’	 acceptance	 and	 under-reporting	 of	 symptoms	 as	 may	 have	 been	 the	 case	
historically	 when	 limited	 treatment	 options	 were	 available.	 Another	 possible	
explanation	 may	 be	 that	 patients	 may	 be	 receiving	 better	 education	 as	 to	 the	
importance	of	quantifying	symptom	severity,	either	through	better	explanation	of	the	
purpose	of	the	metric	to	patients	by	healthcare	staff,	or	through	previous	regular	use	





in	 the	 UK	 due	 to	 mandatory	 NICE	 guidance	 on	 access	 to	 biologics.	 This	 guidance	
specifies	a	minimum	DAS28	score	of	5.1	is	required	in	order	to	commence	a	biologic	
agent	 (162).	 Therefore,	 by	 definition,	 those	 patients	who	have	 been	 commenced	 in	
anti-TNF	 and	 enrolled	 onto	 the	 BSRBR-RA	 will	 have	 to	 have	 met	 this	 minimum	
threshold,	 and	 it	would	 be	 inconceivable	 that	 the	mean	DAS28	 score	 could	 reduce	




In	addition	 to	 the	reduction	 in	baseline	disease	activity	over	 time,	 there	has	been	a	
significant	 reduction	 in	 the	 baseline	 HAQ	 prior	 to	 commencing	 anti-TNF	 of	 0.43,	
demonstrating	that	patients	starting	anti-TNF	are	significantly	less	disabled	at	the	time	
of	 starting	biologics	 in	2010-2013	 compared	with	2001-2010	 (Table	23).	This	 is	 of	
importance	 as	 evidence	 has	 shown	 that	 worsening	 HAQ	 scores	 are	 challenging	 to	





























remission	respectively	(Table	24).	This	highlights	scope	for	 further	 improvement	 in	











In	 both	 the	 sustained	 LDA	 and	 sustained	 remission	 analyses,	 a	 greater	 number	 of	
predictors	were	 identified	 in	 the	 2001-2010	 subgroup	 analysis	 compared	with	 the	
2010-2013	 analysis.	 This	may	 be	 due	 to	 the	 larger	 group	 size	 in	 the	 2001	 –	 2010	
analysis	compared	with	the	2010	–	2013	analysis.	However,	it	is	also	possible	that	the	










0.53	 (95%	 CI	 0.44	 –	 0.63),	 and	 was	 also	 identified	 as	 being	 associated	 with	 both	
sustained	remission	and	LDA	when	the	cohort	was	analysed,	in	both	the	whole	cohort,	
and	in	the	2001	-	2010	subgroup	analyses	(OR	of	0.63,	95%	CI	0.58	–	0.69,	and	OR	0.65,	
95%	 CI	 0.59	 –	 0.71,	 for	 the	 2001-2010	 and	 whole	 cohort	 sustained	 LDA	 analyses	





be	 is	 not	 clear.	 It	 may	 be	 that	 men	 with	 lower	 disease	 activity	 are	 less	 likely	 to	
participate	in	a	research	study,	with	a	resultant	apparent	increase	in	disease	activity	
amongst	men	that	negates	an	effect	of	gender.	It	may	also	be	that	over	the	duration	of	












(0.55	 –	 0.64)	 for	 LDA.	 This	 adds	 further	 support	 to	 the	 hypothesis	 that	 earlier	

















An	 increasing	 swollen	 joint	 count	 was	 significantly	 associated	 with	 an	 increased	
chance	of	achieving	sustained	remission	for	both	the	cohort	as	a	whole,	and	the	2001	
–	2010	subgroup.	This	association	was	maintained	 for	sustained	LDA	 in	 the	2001	–	
2010	subgroup.	Whilst	this	relationship	may	appear	counterintuitive	at	first,	it	could	
be	explained	by	the	fact	that	an	increasing	swollen	joint	count	is	strong	evidence	of	an	








Another	 unexpected	 finding	 was	 that	 an	 increasing	 PGA	 was	 associated	 with	 an	
increased	likelihood	of	achieving	sustained	remission	for	the	whole	cohort	and	2001	–	
2010	 subgroup.	 It	 is	 possible	 that	 those	 patients	with	 active	 inflammatory	 disease	
experience	a	more	fluctuating	level	of	pain	that	means	that	that	when	they	have	active	












associated	 with	 sustained	 remission	 in	 the	 2001-2010	 subgroup	 analysis.	 This	 is	
probably	due	to	the	high	levels	of	multiple	collinearity	that	occurred	when	including	
















subgroup	 (Table	 23).	 Higher	 BMI	 has	 been	 noted	 to	 be	 associated	 with	 poorer	
outcomes	both	 in	early	RA	patients	 (246),	and	 those	with	more	established	disease	





Ex-smoking	 status	 was	 significantly	 associated	 with	 the	 likelihood	 of	 achieving	
sustained	 remission	 and	 LDA	 in	 both	 the	 whole	 cohort	 and	 2001-2010	 subgroup	
analyses.	Whilst	there	was	a	trend	towards	benefit	for	patients	who	had	never	smoked,	
this	did	not	reach	significance.	Whilst	the	association	between	stopping	smoking	and	
improved	 outcomes	 is	 in	 line	with	what	would	 be	 expected,	 it	 is	 surprising	 that	 a	
significant	association	was	not	identified	when	comparing	never	smokers	with	current	
smokers.	It	may	be	that	the	smoking	data	used	in	this	analysis	(never/ever/current)	
were	 too	 crude	 to	 pick	 up	 such	 an	 association	 and	 more	 quantified	 measures	 of	





approach	 failed	to	 identify	an	association	(249).	Such	an	approach	could	be	used	 in	
further	studies	to	specifically	examine	the	association	between	smoking	and	sustained	
remission	or	LDA.	However,	Barnabe	et	al.(220)	were	able	to	identify	an	association	
between	 smoking	 and	 sustained	 remission	 using	 never/ex/current	 categories	 for	





Age	 when	 commencing	 anti-TNF	 appears	 to	 be	 negatively	 associated	 with	 the	
likelihood	of	achieving	sustained	remission	 in	both	 the	whole	cohort	and	 the	2001-






















LDA	 when	 considering	 the	 2010	 –	 2013	 subgroup	 analyses,	 and	 Cimzia™	 use	 was	






agents,	 and	 therefore	will	 have	 been	 used	 to	 treat	 patients	with	 the	worst	 disease	
activity,	greatest	disability	and	longest	disease	duration	when	the	drugs	first	became	














of	 examining	 differences	 between	 drugs	 may	 be	 a	 more	 appropriate	 method	 to	
examine	this	relationship	with	more	certainty.	
	




















clinically	 useful	 predictors	 was	 selected,	 with	 an	 evidence-based	 approach	 using	
results	 from	 the	 systematic	 review,	 and	 the	 issue	 of	 multiple	 collinearity	 between	
variables	 was	 quantified	 and	 addressed	 using	 a	 defined	 methodology	 (stepwise	
regression).	The	fact	that	comparisons	between	the	full	and	reduced	regression	models	
did	not	highlight	significant	changes	in	direction	of	relationships	lends	further	support	
to	 the	 relationships	 identified	 in	 the	 full	 regression	 models,	 and	 minimises	 the	
likelihood	of	identification	of	spurious	relationships	occurring	due	to	chance.	
	
A	 further	 strength	 is	 that	 this	 analysis	 has	 examined	 how	 the	 demographics	 and	
frequency	of	sustained	remission	and	LDA	have	changed	over	time,	and	highlight	how	
improvements	in	clinical	practice	and	treatment	strategies	have	influenced	outcomes.	
By	 stratifying	 the	 analysis,	 these	 results	 provide	 a	 contemporaneous	 assessment	 of	






will	 have	 a	 degree	 of	 selection	 bias	 by	 virtue	 of	 patients	 having	 to	 consent	 to	
participate,	and	clinicians	being	willing	 to	contribute	 to	 the	study.	As	such,	 it	 is	not	
possible	 to	 fully	 quantify	 the	 theoretical	 missing	 data	 from	 patients	 who	 never	
consented,	or	were	never	approached,	 to	 take	part	 in	 the	study.	Additionally,	 in	 the	
analysis	of	longitudinal	outcomes,	there	will	be	variation	in	the	date	that	a	follow-up	






which	 is	 known	 to	 be	 a	 more	 lenient	 definition	 of	 remission	 compared	 to	 more	

























for	 this	 analysis.	 Firstly,	 if	 concomitant	DMARD	data	were	 included,	 should	 this	 be	
DMARD	use	at	baseline	(i.e.	before	the	anti-TNF	is	commenced),	or	as	ongoing	DMARD	








to	 the	 challenges	with	 incorporation	of	 a	 time-varying	 covariate	 into	 a	 longitudinal	









The	 proportion	 of	 patients	 achieving	 sustained	 remission	 and	 LDA	 has	 increased	
significantly	 over	 time,	 although	 patients	 who	 achieve	 this	 outcome	 remain	 in	 the	















10 Modelling	 trajectories	of	 response	 to	anti-TNF	 in	patients	
with	RA	
	
As	 identified	 in	 Chapter	 9,	 certain	 demographic	 and	 clinical	 features	 have	 been	
identified	that	are	associated	with	the	likelihood	of	achieving	sustained	remission	and	
LDA.	 However,	 as	 previously	 described,	 using	 set	 thresholds	 for	 defining	 any	
parameter	(such	as	remission	or	LDA)	creates	difficulties	with	values	that	fall	close	to	
either	 side	 of	 the	 imposed	 threshold.	 Using	 thresholds	 also	 converts	 a	 continuous	
outcome	 such	 as	 the	 DAS28-ESR	 (with	 a	 scale	 0-10)	 into	 a	 categorical	 outcome	
(remission/LDA/MDA/HDA).	This	means	that	DAS28-ESR	values	that	may	be	only	0.1	
points	apart	may	be	allocated	to	different	groups	and	be	allocated	to	the	same	category	
label	as	 scores	 that	are	 less	 close	 to	 them,	but	which	 fall	within	 the	same	category,	
defined	by	the	threshold.	Whilst	conversion	of	a	continuous	variable	to	a	categorical	












Another	 difficulty	 when	 using	 epidemiological	 time-series	 data	 is	 the	 discrepancy	
between	when	the	data	should	have	been	collected,	and	when	it	was	collected.	Because	
the	 previous	 analysis	 in	 Chapter	 9	 required	 identification	 of	 remission/LDA	 at	 two	
sequential	time	points,	it	was	necessary	to	use	the	follow-up	number,	rather	than	the	
	 224	
actual	 date	 of	 completion	 of	 the	 follow-up	 form	 when	 determining	 sustained	














in	 the	 real-world	 clinical	 setting,	 and	 predictors	 associated	 with	 different	 drug	
response	trajectories.	
	
10.2 Objectives of this chapter 
	
1. To	examine	 the	 longitudinal	disease	activity	data	 in	 the	BSRBR-RA	 to	 identify	 if	
there	are	clearly	identifiable	trajectories	of	response	to	anti-TNF	medications.	








10.3 Null hypothesis 
	















identified,	 the	 clinical	 and	 demographic	 features	 of	 patients	 who	 achieve	 these	








three	datasets	 -	one	 ‘full’	 cohort	 including	all	patients	starting	anti-TNF	 from	2001-
2013,	and	two	subgroups	extracted	from	this	dataset;	one	covering	2001-2010,	and	
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(2001	 –	 2010	 and	 2010	 –	 2013)	 from	 the	 analysis	 in	 Chapter	 9	 will	 also	 be	 used	























































starting	 their	 first	 anti-TNF.	 LCMM	 is	 described	 in	 Chapter	 5.	 Analysis	will	 use	 the	
LCMM	package	in	R	and	will	include	two,	three	and	four	classes.	Data	will	be	examined	
by	graphical	plotting	and	the	lowest	Bayesian	information	criterion	(BIC;	Chapter	5;	
5.4.4)	will	 be	used	 to	 select	 the	best-fitting	 class	model	 for	 each	 specific	 dataset.	A	
logistic	or	multinomial	regression	model	will	then	be	used	to	identify	associations	with	
the	previously	outlined	variables	(Table	32	and	Table	33).	For	this	analysis,	baseline	
and	 longitudinal	 datasets	 have	 been	 merged,	 so	 a	 total	 of	 five	 multiply-imputed	
datasets	will	be	used.	As	in	Chapter	9,	regression	analysis	will	be	undertaken	on	each	
imputed	dataset,	and	estimates	combined	using	Rubin’s	rules	(Chapter	5;	5.1.5.1)	to	


















from	 one	 representative	 imputed	 dataset	 are	 shown	 here,	 although	 they	 were	 all	
examined	 individually	 to	 ensure	 uniform	 class	 allocation	 prior	 to	 regression.	 As	
previously	mentioned,	the	dataset	has	been	split	into	the	three	different	groups	(whole	
cohort,	2001	–	2010	subgroup	and	2010	–	2013	subgroup)	and	two,	three	and	four-














clearly	 shows	 that	 there	 appear	 to	 be	 different	 trajectories	 of	 response	within	 the	
whole	cohort	and	different	subgroups	of	the	BSRBR-RA.	It	is	possible	to	see	that	the	
baseline	 disease	 activity	 has	 reduced	 between	 the	 2001-2010	 and	 2001-2013	
subgroups	 for	both	 trajectories	 in	 the	 two-class	model	 (reduced	y-intercept;	Figure	
24b,	 c),	 in	 keeping	with	 results	 presented	 in	 Chapter	 9	which	 showed	 a	 significant	
reduction	in	baseline	disease	activity	(Table	23).	
	
In	 the	2010-2013	subgroup,	 it	appears	 that	 those	 individuals	with	a	 lower	baseline	
disease	 activity	 score	 at	 the	 point	 of	 starting	 anti-TNF	 have	 a	 greater	 chance	 of	
achieving	 sustained	 good	 response,	 with	 good	 and	 poor	 response	 trajectories	
separated	at	baseline	(reduced	y-intercept	for	good	response	trajectory;	Figure	24c,	f	
and	i).	The	greatest	fall	in	disease	activity	occurs	in	the	first	six	months	from	starting	
























Mean	BIC	 2	Classes	 3	Classes		 4	Classes	
Whole	cohort	 219136	 219063	 219032	
2001-2010	subgroup	 200511	 200433	 200403	







two-class	 model	 for	 the	 2010-2013	 subgroup.	 Graphical	 mapping	 of	 the	 different	
LCMM	models	 in	 one	 of	 the	 imputed	 datasets	 (Figure	 24)	 shows	 increasingly	wide	
confidence	 intervals	 in	 the	2010-2013	 subgroup	as	 the	number	of	 classes	 increase,	




























































Variables	 OR	 (95%	CI)	 P	
DAS28-ESR	 0.69	 (0.61	-	0.78)	 <0.001	
2001	–	2010	cohort	–	full	model	
DAS28-ESR	 0.67	 (0.59	-	0.77)	 <0.001	
2010	-	2013	subgroup	–	full	model	
Swollen	joint	count	 0.95	 (0.92	-	1.00)	 0.03	












	 Whole	cohort	 2001	 –	 2010	
subgroup	
2010	–	2013	subgroup	
Good	outcome	 	 	 	























Examining	 the	 whole	 cohort	 and	 the	 2001	 –	 2010	 subgroup,	 the	 relationships	








When	 examining	 the	 variables	 that	 were	 associated	 with	 a	 reduced	 likelihood	 of	














analysis	 (Chapter	 9,	 Table	 27),	with	 a	 higher	 PGA	 being	 associated	with	 a	 reduced	
likelihood	of	achieving	sustained	good	response.	
	
However,	 the	 effect	 of	 increasing	HAQ,	 S:TJR,	 disease	 duration	 and	ESR,	 previously	
identified	 as	 being	 negatively	 associated	with	 the	 likelihood	 of	 achieving	 sustained	















	 Whole	cohort		 2001	–	2010	subgroup	 2010	–	2013	subgroup	
Variables	
in	Model	
Gender,	 HAQ,	 BMI,	 TJC,	 SJC,	
PGA,	ESR,	Age	at	starting	anti-
TNF,	 Smoking	 status,	 Anti-
TNF	 choice,	 Year	 starting	
biologic	
Gender,	 HAQ,	 BMI,	 SJC,	 PGA,	 ESR,	
Age	 at	 starting	 anti-TNF,	 Smoking	
status,	 Anti-TNF	 choice,	 Year	
starting	biologic	
HAQ,	 BMI,	 S:TJR,	 Disease	
duration,	PGA,	ESR	


































































Dataset	 Poor	response,	n	(%)	 Moderate	response,	n	(%)	 Good	response,	n	(%)	
Whole	cohort	 2709	(18.8)		 9264	(64.2)		 2463	(17.1)	
2001	-	2010	 2112	(16.1)		 8749	(66.7)	 2255	(17.2)	




majority	 of	 patients	 taking	 anti-TNF	 appear	 to	 fall	 into	 the	 long-term	 moderate	
response	 category	 (Table	 41).	 Of	 note,	 there	 appears	 to	 be	 an	 increase	 in	 poor	
responders	in	the	2010-2013	cohort.	However,	this	may	be	because	of	the	increased	















Response	trajectory	 Poor	 Moderate	 Good	
Whole	cohort	(2001	–	2013)	
Poor	 0.71	 0.28	 0.01	
Moderate	 0.22	 0.63	 0.15	
Good	response	 0.01	 0.23	 0.77	
2001	–	2010	subgroup	
Poor	response	 0.72	 0.28	 0.01	
Moderate	response	 0.21	 0.65	 0.14	
Good	response	 0.01	 0.22	 0.77	
2010	–	2013	subgroup	
Poor	response	 0.69	 0.28	 0.03	
Moderate	response	 0.24	 0.58	 0.18	






associated	 with	 the	 likelihood	 of	 achieving	 the	 best	 response	 in	 both	 the	 full	 and	
reduced	 regression	 model	 (Table	 43).	 A	 similar	 pattern	 with	 regards	 to	 the	








There	appears	 to	be	a	calendar-year	effect	 in	both	regression	models	 for	 the	whole	
cohort	analysis	(Table	43)	and	a	more	recent	year	of	starting	anti-TNF	is	associated	
with	 an	 increased	 likelihood	 of	 achieving	 sustained	 remission,	 for	 both	 best	 and	
moderate	response	trajectories.	The	choice	of	anti-TNF	agent	(Humira™)	appears	to	be	
associated	with	 achievement	 of	 a	moderate,	 but	 not	 best	 response.	 Longer	 disease	
duration	before	starting	anti-TNF	is	associated	with	a	reduced	likelihood	of	achieving	
	 239	
a	 sustained	 best	 response.	 This	 relationship	 is	 not	 seen	 in	 the	 reduced	 regression	
model	as	the	variable	 is	not	 included	in	the	reduced	regression	model.	However,	an	
increasing	 swollen	 joint	 count	 is	 associated	with	 a	 reduced	 likelihood	 of	 achieving	





		 OR	(95%	CI)	 P	 OR	(95%	CI)	 P	
DAS28-ESR	 0.63	(0.52	-	0.77)	 ≤0.001	 0.83	(0.71	-	0.99)	 0.03	
Disease	duration	 0.99	(0.99	-	1.00)	 0.03	 1.00	(0.99	-	1.00)	 0.31	
ESR	 1.00	(0.99	-	1.00)	 0.35	 1.00	(0.99	-	1.00)	 ≤0.001	
Humira™	 1.06	(0.92	-	1.23)	 0.39	 1.19	(1.07	-	1.33)	 ≤0.001	
Year	starting	biologic	 1.05	(1.02	-	1.07)	 0.00	 1.02	(1.00	-	1.04)	 0.07	
Whole	 cohort	 (2001	 –	 2013)	 reduced	 regression	model.	 Variables	 included	 in	model:	
gender,	HAQ,	DAS28-ESR,	BMI,	TJC,	SJC,	PGA,	ESR,	anti-TNF	agent,	year	starting	biologic.	
DAS28-ESR	 0.63	(0.52	-	0.77)	 ≤0.001	 0.83	(0.70	-	0.98)	 0.03	
SJC	 0.99	(0.98	-	1.01)	 0.29	 0.99	(0.98	-	1.00)	 0.02	
ESR	 1.00	(0.99	-	1.00)	 0.40	 1.00	(0.99	-	1.00)	 ≤0.001	
Humira™	 1.07	(0.92	-	1.23)	 0.38	 1.19	(1.07	-	1.33)	 ≤0.001	





















Variables	 Best	vs	poor	response	 Moderate	 vs	 poor	
response	
		 OR	(95%	CI)	 P	 OR	(95%	CI)	 P	
DAS28-ESR	 0.63	(0.50	-	0.79)	 ≤0.001	 0.84	(0.69	-	1.02)	 0.08	
BMI	 1.01	(1.00	-	1.02)	 0.05	 1.00	(1.00	-	1.01)	 0.32	
Smoking	(ex	vs	current)	 1.20	(1.02	-	1.41)	 0.03	 1.12	(0.98	-	1.27)	 0.09	




DAS28-ESR	 0.62	(0.55	-	0.69)	 ≤0.001	 0.75	(0.68	-	0.82)	 ≤0.001	
BMI	 1.01	(1.00	-	1.02)	 0.04	 1.00	(1.00	-	1.01)	 0.29	
Smoking	(ex	vs	current)	 1.19	(1.01	-	1.40)	 0.04	 1.12	(0.98	-	1.27)	 0.10	
Age	at	starting	biologic	 0.99	(0.99	-	1.00)	 0.04	 1.00	(0.99	-	1.00)	 0.10	
Year	when	starting	anti-TNF	 1.10	(1.05	–	1.15)	 ≤0.001	 1.08	(1.04	–	1.12)	 ≤0.001	
Table	44.	Predictors	of	response	for	three	classes	(2001	-	2010	subgroup)	
	
As	expected,	 the	2010	–	2013	subgroup	analysis	shows	 fewer	associations	 than	 the	
other	two	datasets	(Table	45).	However,	female	gender	appears	to	be	associated	with	
an	increased	likelihood	of	achievement	of	moderate	response	compared	with	a	poor	
outcome,	but	has	no	association	with	 the	best	 response	 trajectory.	The	relationship	








a	 reduced	 likelihood	 of	 achieving	 sustained	moderate	 response	 in	 the	 full,	 but	 not	
reduced	regression	model.	The	direction	of	relationship	of	both	the	swollen	joint	count	
and	PGA	is	opposite	to	the	response	identified	in	the	whole	cohort	and	2001	–	2010	
subgroup	 analysis	 in	 chapter	 9	 for	 the	 same	 variables.	 Finally,	 as	 with	 previous	










	 OR	(95%	CI)	 P	 OR	(95%	CI)	 P	
Gender	 1.10	(0.74	-	1.64)	 0.63	 1.49	(1.07	-	2.07)	 0.02	
SJC	 0.90	(0.85	-	0.96)	 ≤0.001	 0.93	(0.89	-	0.98)	 ≤0.001	
PGA	 0.99	(0.98	-	1.00)	 0.08	 0.99	(0.98	-	1.00)	 0.05	
2010	–	2013	subgroup	reduced	regression	model.	Variables	included	in	model:	HAQ,	BMI,	
S:TJR,	disease	duration,	PGA,	ESR.	
HAQ	 0.71	(0.56	-	0.90)	 ≤0.001	 0.86	(0.71	-	1.05)	 0.15	







2010	–	2013	subgroups.	The	dark	-	 light	 lines	(labelled	 ‘best’,	 ‘good’,	 ‘moderate’	and	 ‘poor’	respectively)	
























Whole	cohort	 465	(3.2)	 7935	(55.0)		 	4792	(33.2)	 	1244	(8.6)	
2001	 –	 2010	
subgroup	 517	(3.9)	 7388	(56.3)		 4163	(31.7)	 1047	(8.0)		
2010	 –	 2013	
















Poor	response	 0.75	 0.24	 0.01	 0.00	
Moderate	response	 0.15	 0.64	 0.20	 0.01	
Good	response	 0.03	 0.23	 0.62	 0.12	













Poor	response	 0.75	 0.25	 0.01	 0.00	
Moderate	response	 0.15	 0.64	 0.21	 0.01	
Good	response	 0.03	 0.23	 0.61	 0.14	











Variables	 OR	(95%	CI)	 P	 OR	(95%	CI)	 P	 OR	(95%	CI)	 P	
	
Whole	cohort	(2001-2013)	full	model	
DAS28-ESR	 0.42	(0.27	-	0.65)	 ≤0.001	 0.50	(0.33	-	0.75)	 ≤0.001	 0.74	(0.49	-	1.12)	 0.15	








DAS28-ESR	 0.42	(0.27	-	0.65)	 ≤0.001	 0.49	(0.33	-	0.75)	 ≤0.001	 0.74	(0.49	-	1.11)	 0.15	




1.08	(1.01	-	1.14)	 0.01	 1.04	(0.99	-	1.10)	 0.11	 1.04	(0.98	-	1.10)	 0.16	
Table	49.	Predictors	of	response	for	four	classes	(whole	cohort	2001	-	2013)	
	








moderate	and	worst	 trajectory,	but	not	with	 the	 likelihood	of	achieving	a	sustained	
best	response	 in	either	 the	 full	or	reduced	regression	model.	A	more	recent	year	of	











Variables	 OR	(95%	CI)	 P	 OR	(95%	CI)	 P	 OR	(95%	CI)	 P	
	 2001	-	2010	subgroup	full	model	
DAS28-ESR	 0.41	(0.25	-	0.65)	 ≤0.001	 0.47	(0.30	-	0.73)	 ≤0.001	 0.71	(0.46	-	1.10)	 0.13	
Year	 starting	
anti-TNF	




DAS28-ESR	 0.56	(0.46	-	0.69)	 ≤0.001	 0.64	(0.53	-	0.78)	 ≤0.001	 0.88	(0.73	-	1.06)	 0.19	
Year	 starting	
anti-TNF	
1.14	(1.04	-	1.24)	 ≤0.001	 1.11	(1.03	-	1.20)	 0.01	 1.10	(1.02	-	1.18)	 0.02	
Table	50.	Predictors	of	response	for	four	classes	(2001	-	2010	subgroup)	
	
Undertaking	 the	same	analysis	 in	 the	2001-2010	subgroup	(Table	50),	 the	negative	
association	 of	 an	 increased	 baseline	 DAS28-ESR	 on	 the	 likelihood	 of	 achieving	
sustained	best	or	good	response	is	maintained	in	the	both	regression	models.	Anti-TNF	














the	 analysis	 that	 there	 are	 distinct	 trajectories	 of	 response	 to	 anti-TNF,	 and	 these	
trajectories	disperse	very	early	during	treatment,	with	the	majority	of	improvement	in	
disease	activity	seen	by	six	months.	The	fact	that	the	trajectories	diverge	so	clearly	by	









response	 to	 anti-TNF	 treatment	would	 expedite	 clinical	 decision	making	 about	 the	
chance	of	future	success	of	continuing	treatment.		
	
Another	 interesting	 finding	 from	 this	 analysis	 is	 the	 absence	 of	 any	 ‘U-shaped’	




such	 secondary	non-response	occurs	 insufficiently	 frequently	 to	 generate	 a	distinct	
response	trajectory	that	is	identifiable	in	the	LCMM	analysis.	It	may	also	be	that	a	six-






























and	may	make	 a	 clinical	 decision	 that	 it	 would	 be	 worthwhile	 persisting	 with	 the	
current	anti-TNF	agent	so	see	if	a	good	response	returns.	The	advantage	of	these	LCMM	
analyses	is	that	the	probability	of	different	future	mean	trajectories	of	response	can	be	
calculated,	 something	 that	 is	 challenging	when	 only	 considering	 current	 or	 disease	
activity.	This	would	be	of	use	to	assist	clinicians	when	trying	to	decide	on	whether	to	




good	response	over	 time	(Table	35),	matching	 the	changes	 in	response	observed	 in	
Chapter	9.	This	adds	further	support	to	the	suggestion	that	earlier	treatment,	at	lower	
DAS28-ESR	scores	and	before	development	of	significant	disability,	as	evidenced	by	




sustained	 best	 and	 good	 response	 trajectories	 than	 when	 using	 a	 pre-determined	
threshold	of	remission	or	LDA.	Of	particular	interest,	is	that	female	gender,	which	was	





to	 be	 less	 likely	 to	 achieve	 sustained	 remission	 when	 using	 the	 DAS28-ESR	 as	 an	
outcome.	 Because	 the	 LCMM	 analysis	 does	 not	 use	 set	 thresholds,	 women	 with	 a	
sustained	 good	 response	 that	may	be	 just	 above	 the	2.6	 threshold	 required	 for	 the	
DAS28	 definition	 of	 remission,	 would	 still	 be	 grouped	 with	 a	 sustained	 good/best	
response	trajectory,	and	this	may	explain	why	this	variable	was	not	identified	in	any	of	








































(four	 classes)	 is	unreliable	when	 considering	 the	2010	–	2013	 subgroup	 (given	 the	
increased	 BIC,	 poorer	 posterior	 probabilities	 and	 evident	 instabilities	 seen	 on	





In	 this	 situation,	 it	 is	 helpful	 to	 take	 a	 pragmatic	 approach	 and	 think	which	model	
would	be	the	most	clinically	useful.	From	a	clinical	standpoint,	if	the	data	were	to	be	
used	in	a	clinical	decision-support	tool,	the	two-class	model	is	the	most	useful,	as	it	is	
useful	 to	 know	 if	 a	 patient	 is	 likely	 to	 respond	 optimally	 to	 a	 drug	 or	 not.	 Having	




2010	 –	 2013	 subgroup),	 rather	 than	more	 historical	 cohorts	 (i.e.	 the	 2001	 –	 2010	








The	 other	 question	 to	 address	 when	 considering	 which	 model	 to	 use	 is	 whoch	
regression	model	to	use?	Should	the	‘full’	regression	model	(which	include	all	a	priori	
variables)	 or	 the	 ‘reduced’	 regression	 model	 (using	 the	 reduced	 set	 of	 variables	
identified	 by	 the	 stepwise	 regression	 modelling	 identified	 in	 Chapter	 9)	 be	 used?	
Examination	of	the	data	(in	both	Chapter	9	and	10)	suggest	that	there	is	actually	very	






Because	 it	 is	 not	 possible	 to	 undertake	 stepwise	 regression	 on	 the	 higher-order	
multinomial	 regression	models	 in	 this	 chapter,	 the	 variables	 identified	 by	 stepwise	
analysis	 were	 selected	 using	 the	 analysis	 from	 Chapter	 9	 which	 is	 not	 optimal.	
Therefore,	whilst	 it	was	helpful	 to	undertake	analysis	using	 the	 reduced	 regression	
models	 (to	 allow	 assessment	 of	 stability	 of	 associations	 within	 the	 full	 regression	
model,	as	well	as	allowing	cross	comparison	with	results	 from	Chapter	9),	 the	most	
appropriate	 regression	 model	 to	 select	 when	 examining	 possible	 predictors	 of	













inspection	 of	 trajectories).	 As	 with	 Chapter	 9,	 missing	 data	 were	 thoroughly	
investigated	 and	 imputation	 appropriately	 applied.	 Attempts	 were	 also	 made	 to	
minimise	 collinearity	 by	 using	 previously	 selected	 variables	 chosen	 by	 stepwise	
regression	from	Chapter	9.	
	
However,	 there	are	also	weakness.	As	discussed	previously,	 the	decision	 to	exclude	
patients’	data	from	the	point	of	switching	anti-TNF	or	to	a	different	biologic,	may	have	
influenced	 the	 trajectories	 identified,	 and	 possibly	 made	 the	 identification	 of	 a	 U-
shaped	secondary	non-response	trajectory	less	likely.	It	is	also	possible	that	the	six-
monthly	frequency	of	the	data	collection	undertaken	in	the	BSRBR-RA	is	not	sufficient	
to	 identify	 all	 possible	 trajectories	 of	 response.	 However,	 collecting	 data	 more	











Another	 possible	 weakness	 in	 this	 analysis	 is	 that	 in	 exploring	 the	 relationships	












sustained	 remission	 without	 exceptionally	 granular	 detail	 on	 the	 underlying	 co-
morbidity.	The	HAQ	could	be	viewed	as	a	global	surrogate	for	‘other	health	conditions’	
that	 might	 result	 in	 functional	 impairment	 (e.g.	 heart	 disease	 may	 impair	 an	
individual’s	ability	to	undertake	some	of	the	activities	of	daily	living	as	well	as	activity	
RA),	and	the	association	identified	between	HAQ	and	sustained	remission	in	Chapter	9	
could	 be	 viewed	 as	 evidence	 that	 this	 should	 be	 explored	 in	more	 depth,	 and	 it	 is	
possible	 that	 predictors	 of	 response	 to	 anti-TNF	may	 differ	 between	 subgroups	 of	
patients	with	different	co-morbidities.	Indeed,	the	relationship	between	co-morbidity	
and	response	to	anti-TNF	in	individuals	with	RA	could	justify	a	further	independent	
body	 of	 work	 in	 its	 own	 right.	 However,	 co-morbidity	 data	 were	 not	 included	 in	
analyses	undertaken	in	this	thesis	for	two	reasons:	Firstly,	no	specific	co-morbidities	
were	identified	as	being	associated	with	sustained	remission	in	the	systematic	review	
(Chapter	 7)	 which	 was	 used	 as	 the	 mechanism	 for	 identifying	 the	 variables	 to	 be	





optimal	 for	 the	 multinomial	 regression	 models	 in	 this	 chapter.	 However,	 it	 is	 not	
possible	to	use	stepwise	regression	models	on	a	multinomial	regression	model,	so	it	
was	 not	 possible	 to	 generate	 specific	 optimised	 regression	 models	 for	 the	 LCMM	
analyses.	 Using	 the	 same	 variables	 between	 the	 analyses	 in	 chapter	 9	 and	 10,	 has	
allowed	comparison	of	results	between	analyses.	
	







it	 gives	 a	 binary	 result	 (good/poor	 response),	 and	 the	 treatment	 trajectories	 and	
associations	identified	in	this	analysis	could	help	clinicians	identify	likely	good/poor	










10.8 Key points from this chapter 
	
• Different	 trajectories	 of	 response	 to	 anti-TNF	 are	 evident	 from	 the	 data	 in	 the	
BSRBR-RA.	
	
• Attainment	 of	 sustained	 good/best	 response	 with	 anti-TNF	 is	 improving	 over	
time.	
	





count,	 PGA,	 HAQ,	 disease	 duration,	 and	 age	 are	 associated	 with	 a	 reduced	


















subject	 (Chapter	7).	Whilst	not	 formally	defined	by	ACR	or	EULAR,	 six	months	was	
selected	as	an	appropriate	length	of	time	to	define	sustained	remission.	In	the	process	
of	undertaking	the	systematic	literature	review,	it	became	apparent	that	not	only	was	
the	 evidence	 for	 sustained	 remission	 scarce,	 but	 it	 was	 clouded	 by	 the	 multiple	
























sought	 to	 approach	 the	problem	of	 identifying	 and	quantifying	 sustained	 remission	
from	two	perspectives:	(1)	using	a	pre-determined	‘DAS28-ESR	threshold’	approach	to	
define	sustained	remission,	and	(2)	using	a	data-driven	approach	to	identify	sustained	





























ESR	 level	 than	 men	 (228),	 and	 it	 is	 possible	 that	 this	 may	 have	 influenced	 this	
relationship.		
	
Other	 factors	 that	 appeared	 to	 negatively	 influence	 the	 likelihood	 of	 achieving	
sustained	remission	with	anti-TNFs	were:	increasing	age;	longer	disease	duration;	and	
higher	 HAQ.	 Methotrexate	 co-prescription	 appeared	 to	 improve	 the	 likelihood	 of	
achieving	sustained	remission.	No	objective	clinical	assessment	parameter	(such	as	the	
swollen	 joint	 count	 or	 inflammatory	marker)	was	 associated	with	 the	 likelihood	 of	









addition	 to	 the	 variation	 in	 the	 outcome	 measures	 used	 between	 the	 six	 included	
	 256	
studies,	 there	was	also	variation	 in	which	version	of	DAS28	was	used,	 and	 in	 some	













allows	 calculation	 of	 composite	 scores	 using	 the	 raw	 component	 data.	 In	 some	
















quantification	 of	 this	 relationship,	 which	 subsequently	 enabled	modification	 of	 the	
	 257	
DAS28-CRP	 to	 form	 a	 new	mDAS28-CRP	 outcome	measure.	 The	mDAS28-CRP	 had	




Detailed	 consideration	 was	 given	 to	 the	 possibility	 of	 using	 the	 newly	 developed	
mDAS28-CRP	with	the	DAS28-ESR	in	the	subsequent	analysis	of	sustained	remission	
and	LDA	where	the	DAS28-ESR	was	not	available,	but	ultimately	it	was	not	included	in	










readily	 understood	 by	 a	 wider	 research	 and	 clinical	 audience,	 without	 requiring	
readers	to	be	familiar	with	the	mDAS28-CRP.	
	







CRP	 interchangeably,	 the	 DAS28-ESR	 was	 chosen	 as	 the	 outcome	 measure	 for	
subsequent	 analysis.	 Results	 from	 the	 systematic	 review	 (Chapter	 7)	were	 used	 to	
guide	the	variables	included	in	the	regression	model,	and	had	highlighted	the	potential	








Results	 showed	 that	 sustained	 remission	and	 sustained	LDA	was	uncommon	 in	 the	
dataset	overall	(just	14.9%	and	26.3%	respectively)	and	in	line	with	results	from	the	
systematic	 review.	 However,	 it	 was	 evident	 that	 there	 had	 been	 significant	
improvement	 in	 these	 outcomes	 over	 time,	 with	 21.6%	 and	 32.3%	 of	 patients	







As	 expected,	 there	 was	 collinearity	 between	 the	 variables	 examined.	 However,	
predictors	 that	 were	 identified	 with	 sustained	 remission	 and	 LDA	were	 identified.	
Female	gender,	 increasing	HAQ,	BMI,	ESR,	Remicade™	use	and	older	age	at	 starting	
anti-TNF	 were	 all	 negatively	 associated	 with	 achieving	 sustained	 remission	 in	 the	
cohort	when	 examined	 as	 a	whole.	 Ex-smoker	 status,	 Humira™	 use	 and	 increasing	
swollen	 joint	 count	 and	 PGA	 were	 all	 positively	 associated	 with	 the	 likelihood	 of	
achieving	sustained	remission.	The	subgroup	analyses	identified	identical	associations	
for	 the	 earlier	 subgroup	 (2001	–	2010),	with	 the	 additional	 negative	 association	of	
increasing	DAS28-ESR	at	baseline	with	sustained	remission,	and	positive	association	
of	non-smoker	status	vs.	current	smoking	status	and	starting	anti-TNF	more	recently.	
The	 2010	 -2013	 subgroup	 only	 identified	 one	 negative	 association	 with	 sustained	
remission	 (the	baseline	HAQ).	 	However,	 collinearity	 existed	between	 the	 variables	
examined.	Stepwise	regression	improved	the	model	fit	for	all	analyses.	Post-stepwise	
regression,	 an	 additional	 three	 predictors	 were	 identified	 for	 the	 2010	 –	 2013	
subgroup;	 disease	 duration	 and	 ESR	 were	 associated	 with	 a	 reduced	 likelihood	 of	
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of	 misclassification	 for	 two-class	 models	 for	 all	 analysis	 (75-79%	 correct	
classification).	The	proportion	of	correct	class	allocation	decreased	as	the	number	of	
classes	increased,	although	the	lowest	level	of	correct	classification	was	still	58%	in	the	









Similar	 predictors	 were	 identified	 for	 sustained	 good	 response	 as	 in	 Chapter	 9,	
although	generally	 fewer	associations	were	 identified	using	LCMM.	One	of	 the	most	
surprising	associations	that	was	not	identified	was	that	female	gender	did	not	appear	
to	be	 a	predictor	of	 response	 in	 any	of	 the	LCMM	analyses,	 unlike	 results	 from	 the	
systematic	 review	(Chapter	7)	and	Chapter	9.	However,	 it	does	 lend	support	 to	 the	
hypothesis	 that	 an	 elevated	 baseline	 ESR	 in	 women	 compared	 to	 men	 may	 be	
confounding	this	relationship.	Further	work	using	the	DAS28-CRP	in	place	of	DAS28-
ESR	would	help	identify	if	this	relationship	is	independent	of	the	ESR.	In	addition,	HAQ	
did	 not	 appear	 to	 be	 associated	with	 sustained	 good	 response	 in	 any	 of	 the	LCMM	

























history	 associated	 with	 the	 patients	 who	 started	 anti-TNF	 when	 it	 first	 became	
available	 (e.g.	 chronic	 intractable	 disease,	 >3	 failed	 synthetic	 DMARDS,	 high	 HAQ	
scores,	 etc.).	 	 Therefore,	 the	 2010	 –	 2013	 subgroup	 analysis	 is	 more	 likely	 to	 be	
representative	of	the	patient	population	starting	anti-TNF	therapy	in	2017,	and	gives	
a	better	indication	of	 likely	outcomes	and	predictors.	Furthermore,	the	2010	-	2013	
subgroup	 three-	 and	 four-class	 LCMM	 analyses	 were	 less	 stable	 (by	 BIC,	 posterior	
probabilities	and	visual	analysis),	a	further	reason	for	selecting	a	two-class	LCMM.	
	









between	using	 the	 two	 versions	 of	 the	DAS28	 is	 essentially	 ‘moving	 the	 goalposts’.	
Furthermore,	 when	 making	 comparisons	 between	 trial	 outcomes	 from	 different	
studies,	this	evidence	strongly	suggests	that	results	of	studies	using	the	same	version	





the	most	widely	used	 score.	 In	 addition,	 the	huge	wealth	of	 existing	data	using	 the	
DAS28,	will	mean	that	the	relevance	of	the	score	will	continue	for	many	years	to	come.	


















outcomes	 (including	 remission,	 LDA	 and	 ‘good/best’	 trajectory)	 has	 improved	






The	 work	 undertaken	 to	 identify	 predictors	 of	 sustained	 remission	 and	 LDA	 has	
identified	predictors	 that	have	a	modifiable	component	(such	as	BMI	and	smoking),	





causality	 cannot	 be	 attributed	 to	 these	 factors.	 Even	 though	 causality	 has	 not	 been	






anti-TNF	 therapy	 is	a	good	 indicator	of	 longer-term	outcomes.	However,	 the	LCMM	
analyses	 go	 further,	 and	 show	 that	 if	 a	 good/best	 response	 is	 not	 achieved	 by	 six	
months,	it	is	unlikely	that	it	will	be	achieved	in	the	next	three	years.	This	could	be	of	
great	use	to	clinicians	in	deciding	what	treatment	decision	to	make	at	six	months	when	















anti-TNFs	 (the	 most	 widely	 used	 class	 of	 biologics	 in	 RA)	 is	 important.	 Another	
strength	 of	 the	work	 undertaken	 in	 this	 thesis	 is	 that	 analysis	 has	 been	 guided	 by	
evidence.	 Firstly,	 by	 establishing	 the	 current	 evidence	 base	 around	 the	 proposed	
question,	 before	 ensuring	 that	 the	 parameters	 used	 to	 identify	 the	 condition	 of	
remission/LDA	were	as	robust	as	possible	(by	examining	the	DAS28-ESR	and	–CRP	in	











is	 that	 as	 these	 data	 are	 observational,	 causality	 cannot	 be	 attributed	 to	 the	
relationships	 identified	 in	 these	 analyses.	 Therefore,	 caution	 must	 be	 exercised	 in	








there	 were	 some	 notable	 variables	 that	 were	 not	 included;	 in	 particular	 co-use	 of	
DMARDs	and	steroids	 (discussed	 in	more	detail	 in	Chapter	9;	9.8).	The	presence	or	
absence	of	antibodies	(RF	and	ACPA;	discussed	in	Chapter	1;	1.2.4	)	would	also	have	
been	 interesting	 to	 examine,	 although	 only	 RF	 data	 are	 available	 from	 BSRBR-RA	
cohort	 from	 inception	 (ACPA	was	 added	 later).	 Genetic	 data	would	have	been	 very	
interesting	to	include,	given	the	strong	influence	of	genetics	on	the	development	of	RA	
(Chapter	 1;	 1.3.1).	 However,	 genetic	 data	 are	 not	 available	 within	 the	 BSRBR-RA,	





over	 time	using	 the	DAS28-ESR.	 It	would	have	been	 interesting	 to	compare	disease	
activity	trajectories	using	other	disease	activity	scores	(such	as	the	SDAI	and	CDAI),	
but	the	absence	of	the	physician	global	score	meant	that	this	was	not	possible.	It	is	also	


















Whilst	 there	 is	 an	 understandable	 focus	 on	 RCTs	 with	 single	 point	 outcomes	 for	
efficacy	 studies	 required	 for	 licencing,	 the	 fact	 there	 were	 only	 six	 observational	












It	 remains	 somewhat	 surprising	 that	 the	 temporal	 component	 of	 remission	 was	
specifically	 excluded	 from	 consideration	 for	 the	 updated	 combined	 ACR/EULAR	
definition	of	remission	in	RA	(170).	The	stated	reason	for	this	was	that	‘the	committee	







nature,	 and	as	demonstrated	 in	 this	 thesis,	 sustained	remission	outcomes	are	more	
difficult	to	achieve	than	point-remission	comparators.	By	failing	to	specify	a	minimum	
time	 for	 sustained	 remission	 in	 the	 ACR/EULAR	 definition,	 the	 studies	 that	 opt	 to	
report	 sustained	 remission	 outcomes	 would	 most	 likely	 have	 the	 appearances	 of	
‘poorer’	outcomes	than	studies	that	only	report	point	remission.	The	result	is	that	there	
is	little	incentive	for	clinical	trials,	particularly	those	of	novel	therapeutics	which	may	
be	 trying	 to	carve	a	niche	 in	 the	(happily)	crowded	marketplace	of	rheumatological	
therapeutics,	to	report	an	outcome	that	would	be	more	difficult	to	achieve	than	point	
remission.	The	lack	of	comparative	outcomes	in	the	literature	would	mean	any	study	
of	 a	 novel	 therapeutic	 demonstrating	 a	 realistic	 (but	 likely	 low)	 rate	 of	 sustainable	
remission	would	struggle	to	gain	traction	within	the	marketplace.		
		
Some	 point	 to	 the	 fact	 that	 radiological	 outcomes	 may	 adequately	 quantify	 the	
temporal	 component	 of	 response	 to	 a	 drug	 (254),	 suggesting	 that	 absence	 of	
radiological	progression	of	damage	quantifies	sustained	good/optimal	response	in	a	
clearly	quantifiable	way.	However,	the	problem	with	using	a	radiological	outcome	to	
quantify	 sustained	 remission	 is	 that	 it	 does	 not	 represent	 the	 fluctuating	 temporal	
patient	experience	of	RA,	one	of	the	most	important	aspects	of	treating	any	illness.	
	











clinicians	 alike.	 Bearing	 this	 in	mind,	 the	 question	 remains;	 is	 it	 realistic	 to	 expect	
everyone	to	reach	remission	as	defined	by	any	composite	outcome	measure?	
	
Another	argument	against	having	a	 formalised	definition	of	 ‘sustained	 remission’	 is	




achieve	 the	 threshold	 and	 become	 artificially	 grouped	with	 patients	who	 are	more	









A	 potential	 solution	 to	 the	 problem	 of	 applying	 artificial	 thresholds	 to	 individual	
patient	data	(a	top-down	approach)	is	to	allow	the	‘data	to	speak	for	themselves’	in	the	
form	of	 the	 trajectory	analysis	 (a	bottom-up	approach).	The	analysis	undertaken	 in	
Chapter	 10	 demonstrated	 that	 even	 in	 the	 smallest	 subgroup	 analysis	 (~1300	
patients),	 it	 was	 possible	 to	 reliably	 identify	 at	 least	 two	 common	 trajectories	 of	
response,	and	the	proportion	of	patients	achieving	the	best	outcome	trajectory	(38%)	
was	similar	to	the	proportion	of	patients	achieving	sustained	LDA	by	threshold	analysis	
(32%)	 in	 the	 most	 recent	 subgroup	 analysis	 (2010	 –	 2013).	 There	 were	 fewer	
‘statistically	significant’	associations	identified	(at	a	p-value	≤	0.05)	using	this	method	




majority	 of	 medical	 evidence	 rests,	 and	 is	 the	 most	 widely-accepted	 method	 of	
	 268	




response	 for	 any	 patient.	 What	 has	 been	 demonstrated	 is	 that	 there	 are	 multiple	









the	 proposed	 use	 intended.	 Thresholds	 are	 undoubtedly	 useful	 in	 quantifying	
outcomes	within	a	given	population	and	can	present	clear	and	relatively	unambiguous	
population-level	 results	 and	 associations	 (giving	 a	 clear	 ‘snapshot’	 of	 outcomes	 at	
given	time-points).	However,	it	often	requires	dichotomisation	of	continuous	variables,	
as	well	as	applying	unrealistic	assumptions	(i.e.	everyone	is	followed-up	at	exactly	6-




up	 times	 can	 be	 used	 and	 continuous	 scores	 are	 not	 artificially	 dichotomised).	
Therefore,	results	may	be	viewed	as	more	representative	of	the	 ‘true’	picture	of	the	
real-world	 situation,	 and	 are	 more	 amenable	 to	 adaptation	 to	 develop	 predictive	















combination	 of	 uncertainties	 from	 studies	 undertaken	 with	 different	 primary	
hypotheses	 may	 seem	 heretical	 from	 a	 frequentist	 standpoint,	 but	 tailoring	 and	
updating	 estimates	 of	 likelihood	 of	 a	 certain	 outcome	 for	 an	 individual,	 based	 on	
experience	and	evidence	(from	multiple	sources)	is	exactly	what	a	clinician	does	every	
day,	and	is	the	epitome	of	a	Bayesian	approach.	The	difficulty	until	recently,	has	been	
the	 ability	 to	 quantify	 this	 ‘clinical	 acumen’	 or	 ‘gut	 feeling’,	 in	 a	 way	 that	 can	 be	
reproducibly	 used	 and	 at	 scale.	 However,	 with	 the	 significant	 increases	 in	
computational	 power	 available	 to	 researchers	 today,	 and	 rapid	 advance	 in	
understanding	and	use	of	machine	learning,	neural	networks	and	artificial	intelligence	




to	 analyse	 existing	 genomic	 and	 histopathological	 registry	 data	 to	 provide	




up-to-the-minute	 evidence-based	 recommendations	 for	 treatment	 for	 individual	
patients,	 based	 on	 their	 clinical	 presentation	 and	 histological	 diagnosis.	 Trials	 are	
currently	 underway	 to	 use	 this	 technology	 to	 help	 guide	 clinicians’	 treatment	
recommendations	(255).	
	
This	 approach	 could	 be	 applied	 to	 the	 treatment	 of	 RA.	 Indeed,	 given	 the	multiple	
longitudinal	 RA	 registries,	 clinical	 trial	 and	 genomic	 databases	 with	 structured	
datasets,	 the	 application	 of	machine	 learning	 and	AI	 algorithms	 to	 provide	 tailored	
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practiced.	 There	 are	 ethical	 issues	 too.	 If	 an	 adverse	 event	 occurs	 due	 to	 an	 AI	
generated	recommendation,	who	is	responsible?	How	can	clinicians	be	sure	that	AI	is	
making	decisions	in	the	best	interests	of	the	individual,	and	not	in	the	best	interests	of	








of	 action	 (such	 as	 rituximab	 or	 tocilizumab),	 as	 well	 as	 investigating	 if	 other	
longitudinal	 outcomes	 (such	 as	 disability)	match	 those	 as	measured	 by	 the	DAS28.	
Furthermore,	a	specific	analysis	focusing	on	the	effect	of	the	use	of	DMARDs	as	a	time-















multiple	 sources	 (different	 registries,	 existing	 clinical	 trial	 data	 etc.)	 to	 build	 a	
predictive	online	data	tool.	This	has	already	been	achieved	in	the	field	of	osteoporosis	




thesis).	 LCMM-based	 ‘trajectories’	 could	 then	 use	 real-time	DAS28	 scores	 (or	 SDAI,	
CDAI	etc.)	from	patients	as	treatment	is	commenced,	to	provide	updated	likelihoods	of	
achieving	 sustained	 remission	 as	 treatment	 progresses,	 allowing	 clinicians	 and	
patients	the	option	to	switch	treatments	earlier	if	desired	outcomes	are	not	likely	to	be	


























Clinical baseline form version 11.1  07/07/2016 
Gender: Male Female 
Please complete the following PATIENT information  
 
BSR Biologics Register – Rheumatoid Arthritis 
Clinical Baseline Form 
 
ID 
For office use only 
Form completion date (today’s date): 
Hospital Reg. No: 
NHS No: 
Consultant Rheumatologist:  




Date of birth: 
 















D D M M Y Y Y Y 
D D M M Y Y Y Y 
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 2 
Clinical baseline form version 11.1  07/07/2016 
  








2a. What was the year of diagnosis?  
If NO, can you specify the other diagnosis? 
1. Does the patient have Rheumatoid Arthritis? Yes No 
1a. Does the patient have ACPA (anti-CCP) positive RA? Yes No Don’t Know 
 2b. What year was this patient first seen by a rheumatologist? 
3. ACR Criteria (please indicate which of the following apply to the patient): 
Morning stiffness >1 hour (ever) 
Arthritis or deformity/damage of three or more joint areas (PIP, MCP, 
wrist, elbow, knee, ankle, MTP) (now) 
Arthritis/deformity of hand/joint (now) 
Symmetry 
Nodules (ever) 
Rheumatoid factor positive (t 1/40) (ever) 
Erosions on hand or feet x-ray
 










Other (please specify) 
Don’t 

















































5. Joint replacements/surgery: Has the patient ever had any of the following?  
Total knee replacement 
Total hip replacement 
Total shoulder replacement 
Total elbow replacement 
Wrist/hand/ankle/foot surgery 
Neck surgery 
Unilateral  Bilateral 
6. Please indicate the current disease activity (i.e. at the time the patient started the new 
drug) 
7. Drug therapy: Please list all the patient’s current treatment, for any indication  
Total DAS score (if known): 
 
 
For patients starting a biosimilar - If DAS 28 is unavailable 
 
According to the case notes, was the patient in low disease activity /remission at the point of 
switch to the biosimilar?      Yes          No 
mm 
OR 
28 swollen joint count 
ESR 
CRP 
28 tender joint count 
Patient global assessment (VAS) 
(Out of 100) 
Date DAS28 taken: 
 
____/______/_______ 
 DD      MM       YYYY 
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Clinical baseline form version 11.1  07/07/2016 
8. New Biologic/ Biosimilar Therapy (please use trade name):  
 
 
 Biologic therapy DAS28 prior to starting Start date Stop date Reason for stopping 
1      
2      
3      
4      
 
Is this the patient’s first exposure to a biologic/ biosimilar agent? 
If No, please  
give details below Yes No 
Is the patient still on biologic/biosimilar therapy? If NO, please give details  on a separate sheet Yes No 







Is the patient switching from an originator e.g. Remicade directly to a biosimilar  
of the same product, i.e. Inflectra or Remsima? 
Yes No 
Please indicate the date of first therapy dose: 
Frequency: Please also indicate the average dose and unit: 
IV Is this delivered intravenously or subcutaneously?  SC 





D D M M Y Y Y Y 
9. Is the patient currently receiving DMARD therapy? 
If Yes, please indicate which DMARD(s) and current dose. 
 
Yes No 
DMARD Started                            (please tick) mg Frequency 
Date Started 
D D M M Y Y 
Methotrexate          
Azathioprine          
Cyclophosphamide          
Cyclosporine          
Leflunomide          
Other :           
 












Clinical baseline form version 11.1  07/07/2016 
Has the patient EVER had any of the following drugs? 
























If patient has started or stopped the same drug more than twice please give details on an additional sheet 




















If currently receiving steroids, please indicate dose:  




Clinical baseline form version 11.1  07/07/2016 
  
‡If the patient has (or has ever had) cancer please specify date of diagnosis and site(s): 
*If the patient is diabetic is (s)he:  
Insulin dependent Tablet controlled Diet controlled 
11. Co-morbidity:  
 
Has the patient ever had (i.e. required treatment for) any of the following illnesses? Please tick all 
that apply                          
 




Yes No Year of onset 






































































13. Blood pressure: what is the patient’s current (i.e. at the time that the biologic agent was 





14. Height and weight: what is the patient’s current (i.e. at the time that the biologic agent was 





This form should be accompanied by the 
following pre-biologic therapy patient-
completed forms: 
HAQ 
Thank you for completing this form! 
BSRBR-RA 
Arthritis Research UK Centre for Epidemiology 
Unit 4 Rutherford House 
Manchester Science Park 




Please return to:  






16. Has the patient had a QuantiFERON, ELISPOT (or other Gamma interferon based 







12. Smoking status: Is the patient a:  
Current smoker Ex-smoker Never-smoked 
17. Has the patient received the Herpes zoster vaccine? 
 
Yes No Don’t know Date 
DaDate 
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  Biologic Studies Group 
BSRBR RA 





























of	Bath,	undertake	 to	adhere	 to	 the	attached	guidelines	 “Information	Governance	 in	
Health	and	Social	Care	Research”	which	 is	a	 framework	 for	handling	 information	 in	a	









The University of Manchester 
Manchester Science Park 
Manchester
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and	 research,	 data	 security	 (including	 the	 storage	 of	 data	 (hard-copy	 and	 computer	
data),	the	electronic	transfer	of	data	and	the	destruction	of	data).	
	














I	 agree	 to	be	held	 fully	 responsible	 for	 this	data	adhering	 to	 the	Data	Protection	Act	
1998,	once	it	is	transferred	from	The	University	of	Manchester.	Once	the	transfer	has	




I	agree	 to	ensure	 that	all	persons	handling	 the	BSRBR-RA	data	as	part	of	 this	project	




















and	 therefore	 all	 proposed	 abstracts/manuscripts/reports	 and	 presentations	 arising	
from	 this	 data	 must	 be	 circulated	 for	 review	 to	 all	 BSRBR-RA	 stakeholders	 prior	 to	
submission	via	the	BSRBR-RA	offices	in	Manchester.		Therefore,	I,	Philip	Hamann	agree	
to	adhere	to	the	following	timescales	for	circulation	of	data/results	prior	to	submission,	



















For	 archiving	 purposes,	 all	 relevant	working	 analysis	 files	 should	 be	 returned	 to	 the	




provide	 details	 of	 any	 statistical	 software	 tools	 used	 and	 the	 final	 versions	 of	 the	
article/papers/abstracts.	
	
Please	 return	 all	 files	 to	 the	 BSRBR-RA	Database	Manager	 by	 an	 agreed	method.	 To	









(i)	 For	 BSRBR	 data	 issues,	 please	 contact	 the	 BSRBR	 database	 manager	
katie.mcgrother@manchester.ac.uk	or	phone	0161	306	1893.	




This	 form	 is	 valid	 for	 the	 period	 of	2	 years	 from	 the	 date	 shown	 below.	 Should	 the	
project	take	longer	than	1	year,	this	will	need	to	be	discussed	with	BSRBR-RA	and	a	new	
Data	Release	Form	will	need	to	be	completed.	
	
	
(5) LAY	SUMMARY	OF	DATA	
	
	
	
See	Exhibit	B	
Signed____ ________________	
	
Print	name___Philip	Hamann____________	
	
Dated_________07/07/2016	____________	
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